<!DOCTYPE article
 PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.2 20190208//EN" "JATS-archivearticle1.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="preprint"><?all-math-mml yes?><?use-mml?><?origin ukpmcpa?><front><journal-meta><journal-id journal-id-type="nlm-ta">bioRxiv</journal-id><journal-title-group><journal-title>bioRxiv : the preprint server for biology</journal-title></journal-title-group><issn pub-type="epub">2692-8205</issn></journal-meta><article-meta><article-id pub-id-type="manuscript">EMS199093</article-id><article-id pub-id-type="doi">10.1101/2024.09.26.615223</article-id><article-id pub-id-type="archive">PPR917447</article-id><article-version-alternatives><article-version article-version-type="status">preprint</article-version><article-version article-version-type="number">2</article-version></article-version-alternatives><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Oncogenic and teratogenic effects of <italic>Trp53</italic><sup>Y217C</sup>, an inflammation-prone mouse model of the human hotspot mutant <italic>TP53</italic><sup>Y220C</sup></article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name><surname>Jaber</surname><given-names>Sara</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Eldawra</surname><given-names>Eliana</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Rakotopare</surname><given-names>Jeanne</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Simeonova</surname><given-names>Iva</given-names></name><xref ref-type="aff" rid="A2">2</xref></contrib><contrib contrib-type="author"><name><surname>Lejour</surname><given-names>Vincent</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Gabriel</surname><given-names>Marc</given-names></name><xref ref-type="aff" rid="A3">3</xref></contrib><contrib contrib-type="author"><name><surname>Cañeque</surname><given-names>Tatiana</given-names></name><xref ref-type="aff" rid="A4">4</xref></contrib><contrib contrib-type="author"><name><surname>Volochtchouk</surname><given-names>Vitalina</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Licaj</surname><given-names>Monika</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Fajac</surname><given-names>Anne</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Rodriguez</surname><given-names>Raphaël</given-names></name><xref ref-type="aff" rid="A4">4</xref></contrib><contrib contrib-type="author"><name><surname>Morillon</surname><given-names>Antonin</given-names></name><xref ref-type="aff" rid="A3">3</xref></contrib><contrib contrib-type="author"><name><surname>Bardot</surname><given-names>Boris</given-names></name><xref ref-type="aff" rid="A1">1</xref><xref ref-type="aff" rid="A5">5</xref><xref ref-type="corresp" rid="CR1">*</xref></contrib><contrib contrib-type="author"><name><surname>Toledo</surname><given-names>Franck</given-names></name><xref ref-type="aff" rid="A1">1</xref><xref ref-type="aff" rid="A6">6</xref><xref ref-type="corresp" rid="CR1">*</xref></contrib><aff id="A1"><label>1</label>Genetics of Tumor Suppression, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/04t0gwh46</institution-id><institution>Institut Curie</institution></institution-wrap>, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/02feahw73</institution-id><institution>CNRS</institution></institution-wrap> UMR3244, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/02en5vm52</institution-id><institution>Sorbonne University</institution></institution-wrap>, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/013cjyk83</institution-id><institution>PSL University</institution></institution-wrap>, <city>Paris</city>, <country country="FR">France</country></aff><aff id="A2"><label>2</label>Chromatin dynamics, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/04t0gwh46</institution-id><institution>Institut Curie</institution></institution-wrap>, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/02feahw73</institution-id><institution>CNRS</institution></institution-wrap> UMR3664, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/02en5vm52</institution-id><institution>Sorbonne University</institution></institution-wrap>, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/013cjyk83</institution-id><institution>PSL University</institution></institution-wrap>, <city>Paris</city>, <country country="FR">France</country></aff><aff id="A3"><label>3</label>Non Coding RNA, Epigenetic and Genome Fluidity, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/04t0gwh46</institution-id><institution>Institut Curie</institution></institution-wrap>, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/02feahw73</institution-id><institution>CNRS</institution></institution-wrap> UMR3244, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/02en5vm52</institution-id><institution>Sorbonne University</institution></institution-wrap>, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/013cjyk83</institution-id><institution>PSL University</institution></institution-wrap>, <city>Paris</city>, <country country="FR">France</country></aff><aff id="A4"><label>4</label>Chemical Biology, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/04t0gwh46</institution-id><institution>Institut Curie</institution></institution-wrap>, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/02feahw73</institution-id><institution>CNRS</institution></institution-wrap> UMR3666, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/02vjkv261</institution-id><institution>INSERM</institution></institution-wrap> U1143, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/013cjyk83</institution-id><institution>PSL University</institution></institution-wrap>, <city>Paris</city>, <country country="FR">France</country></aff><aff id="A5"><label>5</label>Signaling and Neural Crest Development, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/04t0gwh46</institution-id><institution>Institut Curie</institution></institution-wrap>, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/02feahw73</institution-id><institution>CNRS</institution></institution-wrap> UMR3347, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/02vjkv261</institution-id><institution>INSERM</institution></institution-wrap> U1021, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/03xjwb503</institution-id><institution>Université Paris-Saclay</institution></institution-wrap>, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/013cjyk83</institution-id><institution>PSL University</institution></institution-wrap>, <city>Orsay</city>, <country country="FR">France</country></aff><aff id="A6"><label>6</label>Hematopoietic and Leukemic Development, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/03wxndv36</institution-id><institution>Centre de Recherche Saint-Antoine</institution></institution-wrap>, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/02vjkv261</institution-id><institution>INSERM</institution></institution-wrap> UMRS938, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/02en5vm52</institution-id><institution>Sorbonne University</institution></institution-wrap>, <city>Paris</city>, <country country="FR">France</country></aff></contrib-group><author-notes><corresp id="CR1">
<label>*</label>For correspondence: <email>franck.toledo@sorbonne-universite.fr</email>; <email>boris.bardot@curie.fr</email>.</corresp></author-notes><pub-date pub-type="nihms-submitted"><day>01</day><month>10</month><year>2024</year></pub-date><pub-date pub-type="preprint"><day>29</day><month>09</month><year>2024</year></pub-date><permissions><ali:free_to_read/><license><ali:license_ref>https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This work is licensed under a <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">CC BY 4.0 International license</ext-link>.</license-p></license></permissions><abstract><p id="P1">Missense “hotspot” mutations localized in six p53 codons account for 20% of <italic>TP53</italic> mutations in human cancers. Hotspot p53 mutants have lost the tumor suppressive functions of the wildtype protein, but whether and how they may gain additional functions promoting tumorigenesis remain controversial. Here we generated <italic>Trp53</italic><sup>Y217C</sup>, a mouse model of the human hotspot mutant <italic>TP53</italic><sup>Y220C</sup>. DNA damage responses were lost in <italic>Trp53</italic><sup>Y217C/Y217C</sup> cells, and <italic>Trp53</italic><sup>Y217C/Y217C</sup> fibroblasts exhibited increased chromosome instability compared to <italic>Trp53</italic><sup>-/-</sup> cells. Furthermore, <italic>Trp53</italic><sup>Y217C/Y217C</sup> male mice died earlier than <italic>Trp53</italic><sup>-/-</sup> males, with more aggressive thymic lymphomas. This correlated with an increased expression of inflammation-related genes in <italic>Trp53</italic><sup>Y217C/Y217C</sup> thymic cells compared to <italic>Trp53</italic><sup>-/-</sup> cells. Surprisingly, we recovered only one <italic>Trp53</italic><sup>Y217C/Y217C</sup> female for 22 <italic>Trp53</italic><sup>Y217C/Y217C</sup> males at weaning, a skewed distribution explained by a high frequency of <italic>Trp53</italic><sup>Y217C/Y217C</sup> female embryos with exencephaly and the death of most <italic>Trp53</italic><sup>Y217C/Y217C</sup> female neonates. Strikingly however, when we treated pregnant females with the anti-inflammatory drug supformin (LCC-12) we observed a five-fold increase in the proportion of viable <italic>Trp53</italic><sup>Y217C/Y217C</sup> weaned females in their progeny. Together, these data suggest that the p53<sup>Y217C</sup> mutation not only abrogates wildtype p53 functions but also promotes inflammation, with oncogenic effects in males and teratogenic effects in females.</p></abstract><kwd-group><kwd>hotspot p53 mutant</kwd><kwd>p53<sup>Y220C</sup></kwd><kwd>gain of function</kwd><kwd>exencephaly</kwd><kwd>inflammation</kwd><kwd>sex-specific effects</kwd></kwd-group></article-meta></front><body><sec id="S1" sec-type="intro"><title>Introduction</title><p id="P2">Somatic alterations in the <italic>TP53</italic> gene, encoding the tumor suppressor p53, are the most common events in human tumors (<xref ref-type="bibr" rid="R34">Hollstein et al., 1991</xref>). The p53 protein is a stress sensor stabilized and activated in response to potentially oncogenic insults. In its tetrameric active form, wildtype (WT) p53 can trigger a transcriptional program to induce various responses including cell cycle arrest, senescence, apoptosis or metabolic changes (<xref ref-type="bibr" rid="R7">Beckerman and Prives, 2010</xref>). In human cancers, about 75% of all <italic>TP53</italic> alterations are missense mutations, and the eight most frequent (“hotspot”) missense mutations (R175H, Y220C, G245S, R248Q, R248W, R273H, R273C and R282W) affect six residues localized in the p53 DNA-binding domain (DBD) and account for 20% of all <italic>TP53</italic> mutations (<xref ref-type="bibr" rid="R30">Hainaut and Pfeifer, 2016</xref>). The fact that most <italic>TP53</italic> mutations are missense substitutions suggested that cells expressing mutant p53 might have a selective advantage over cells lacking p53, and evidence for this was first gained by expressing various p53 mutants in p53-null cells and observing enhanced tumorigenic potential in nude mice or increased plating efficiency in agar cell culture (<xref ref-type="bibr" rid="R17">Dittmer et al., 1993</xref>). Mouse models expressing hotspot p53 mutants next helped to define potential mechanisms accounting for accelerated tumorigenesis. First, a dominant-negative effect (DNE) may be observed in heterozygotes, if the mutant p53 inhibits the WT p53 protein in hetero-tetramers (<xref ref-type="bibr" rid="R26">Gencel-Augusto and Lozano, 2020</xref>). Evidence that this mechanism accounts for accelerated tumorigenesis was notably reported in human leukemia (<xref ref-type="bibr" rid="R11">Boettcher et al., 2019</xref>). A second mechanism is a gain-of-function (GOF), i.e. the acquisition by mutant p53 of new oncogenic properties (<xref ref-type="bibr" rid="R3">Amelio and Melino, 2020</xref>; <xref ref-type="bibr" rid="R77">Stein et al., 2020</xref>). Although the DNA sequence specificity of p53 mutants is impaired, leading to a loss of WT functions (LOF), many p53 mutant proteins are stabilized in the cell and might engage in aberrant interactions with other transcription factors, chromatin-modifying complexes or DNA helicase subunits, leading to the acquisition of GOF phenotypes (<xref ref-type="bibr" rid="R46">Kim and Deppert, 2007</xref>; <xref ref-type="bibr" rid="R64">Pfister and Prives, 2017</xref>; <xref ref-type="bibr" rid="R96">Zhao et al., 2024</xref>). However, a few recent studies challenged the pathological importance of mutant p53 GOF, or at least its relevance in anti-cancer therapeutic strategies (<xref ref-type="bibr" rid="R5">Aubrey et al., 2018</xref>; <xref ref-type="bibr" rid="R11">Boettcher et al., 2019</xref>; <xref ref-type="bibr" rid="R89">Wang et al., 2023</xref>). An alternative hypothesis emerged, postulating that the tumorigenic properties of a p53 mutant might result from a separation-of-function (SOF), if the mutant retains pro-proliferative or pro-survival functions of WT p53 while losing its tumor suppressive activities (<xref ref-type="bibr" rid="R45">Kennedy and Lowe, 2022</xref>). The concept of SOF was first proposed for <italic>TP53</italic> exon-6 truncating mutations, which mimic a naturally occurring alternative p53 splice variant (<xref ref-type="bibr" rid="R72">Shirole et al., 2016</xref>), but may apply to some p53 missense mutations, for example p53<sup>R248W</sup> (<xref ref-type="bibr" rid="R37">Humpton et al., 2018</xref>). Importantly, the analysis of various mutant p53 alleles <italic>in vivo</italic> appears crucial for a better understanding of their contribution to tumorigenesis, because GOF/SOF phenotypes may vary depending on the mutated residue, its specific mutation, the cellular context or genetic background (<xref ref-type="bibr" rid="R16">Dibra et al., 2024</xref>; <xref ref-type="bibr" rid="R33">Hanel et al., 2013</xref>; <xref ref-type="bibr" rid="R42">Kadosh et al., 2020</xref>; <xref ref-type="bibr" rid="R47">Kim and Lozano, 2018</xref>; <xref ref-type="bibr" rid="R48">Kotler et al., 2018</xref>; <xref ref-type="bibr" rid="R57">McCann et al., 2022</xref>; <xref ref-type="bibr" rid="R90">Xiong et al., 2022</xref>).</p><p id="P3">In human cancers, the <italic>TP53</italic><sup><italic>Y220C</italic></sup> mutation is the most frequent missense mutation outside of the DNA-binding surface of p53 (<xref ref-type="bibr" rid="R30">Hainaut and Pfeifer, 2016</xref>). The somatic <italic>TP53</italic><sup><italic>Y220C</italic></sup> mutation accounts for over 100,000 new cancer cases per year worldwide, including solid tumors and myeloid neoplasms, and a germline <italic>TP53</italic><sup><italic>Y220C</italic></sup> mutation was reported in 15 families with the Li-Fraumeni syndrome (LFS) of cancer predisposition (<xref ref-type="bibr" rid="R12">Bouaoun et al., 2016</xref>; <xref ref-type="bibr" rid="R27">Gener-Ricos et al., 2024</xref>). The mutation causes a structural change in the DBD localized at the periphery of the β–sandwich region of the protein, far from the surface contact of DNA. The mutation from a tyrosine to a cysteine markedly lowers the thermodynamic stability of the DBD, leading to a largely unfolded and inactive protein at body temperature (<xref ref-type="bibr" rid="R40">Joerger et al., 2006</xref>), and a molecule designed to bind p53<sup>Y220C</sup> and restore WT protein conformation appears as a promising anti-cancer drug (<xref ref-type="bibr" rid="R19">Dumbrava et al., 2022</xref>). Analyses of the impact of p53<sup>Y220C</sup> in cancer cell lines led to conflicting results. On one hand, overexpression of p53<sup>Y220C</sup> in a p53-null cell line increased its capacity for migration or invasion (<xref ref-type="bibr" rid="R97">Zhou et al., 2022</xref>), and a decreased expression of p53<sup>Y220C</sup>, caused by RNA interference or various chemical compounds, promoted cell death or decreased the migratory or invasive capacities of cells (<xref ref-type="bibr" rid="R82">Tseng et al., 2022</xref>; <xref ref-type="bibr" rid="R86">Vikhanskaya et al., 2007</xref>; <xref ref-type="bibr" rid="R97">Zhou et al., 2022</xref>). On the other hand, the removal by CRISPR/Cas9 of p53 mutants with reported GOF - including p53<sup>Y220C</sup> - in diverse cancer cell lines had no significant impact on cell survival or proliferation, and the cell death caused by RNA interference against p53<sup>Y220C</sup> might result from non-specific toxic effects (<xref ref-type="bibr" rid="R89">Wang et al., 2023</xref>). Here, to gain a better understanding of the impact of the p53<sup>Y220C</sup> mutation <italic>in vivo</italic>, we generated a mouse model with a targeted <italic>Trp53</italic><sup>Y217C</sup> mutation - the mouse equivalent to human <italic>TP53</italic><sup>Y220C</sup> (<xref ref-type="supplementary-material" rid="SD1">Figure S1</xref>) - and analyzed animals and cells carrying one or two copies of the mutant allele.</p></sec><sec id="S2" sec-type="results"><title>Results</title><sec id="S3"><title>Targeting of a p53<sup>Y217C</sup> mutation in the mouse</title><p id="P4">We used homologous recombination in 129/SvJ ES cells to target the p53<sup>Y217C</sup> mutation at the mouse <italic>Trp53</italic> locus. Mice expressing p53<sup>Y217C</sup> conditionally were generated by using a targeting vector containing transcriptional stops flanked by LoxP sites (LSL) upstream of coding sequences, and the p53<sup>Y217C</sup> mutation in exon 6 (<xref ref-type="fig" rid="F1">Figure 1A-D</xref>). <italic>Trp53</italic><sup>+/LSL-Y217C</sup> mice were then crossed with mice carrying the PGK-Cre transgene (<xref ref-type="bibr" rid="R50">Lallemand et al., 1998</xref>) to excise the LSL cassette and obtain <italic>Trp53</italic><sup>+/Y217C</sup> mice, expressing the mutant protein constitutively. After two backcrosses over a C57BL/6J background, we prepared mouse embryonic fibroblasts (MEFs) from intercrosses of <italic>Trp53</italic><sup>+/Y217C</sup> mice (<xref ref-type="fig" rid="F1">Figure 1E</xref>). We extracted RNAs from <italic>Trp53</italic><sup>Y217C/Y217C</sup> MEFs then sequenced p53 mRNAs to verify that the p53<sup>Y217C</sup> coding sequence was identical to the wildtype p53 (p53<sup>WT</sup>) sequence, except for the desired missense mutation and a silent mutation introduced to facilitate mouse genotyping (<xref ref-type="fig" rid="F1">Figure 1F</xref>). The quantification of p53 mRNA levels from WT and <italic>Trp53</italic><sup>Y217C/Y217C</sup> MEFs next revealed similar transcription from both alleles (<xref ref-type="fig" rid="F1">Figure 1G</xref>).</p></sec><sec id="S4"><title>Deficient p53-dependent stress responses in <italic>Trp53</italic><sup>Y217C/Y217C</sup> cells</title><p id="P5">We used western blots to analyze protein extracts from <italic>Trp53</italic><sup>+/+</sup>, <italic>Trp53</italic><sup>+/-</sup>, <italic>Trp53</italic><sup>+/Y217C</sup>, <italic>Trp53</italic><sup>Y217C/Y217C</sup> and <italic>Trp53</italic><sup>-/-</sup> MEFs, unstressed or treated with Nutlin, an antagonist of Mdm2, the E3 ubiquitin ligase for p53 (<xref ref-type="bibr" rid="R84">Vassilev et al., 2004</xref>). Results indicated a high increase in p53 abundance in untreated and Nutlin-treated <italic>Trp53</italic><sup>Y217C/Y217C</sup> MEFs and a moderate increase in untreated and Nutlin-treated <italic>Trp53</italic><sup>+/Y217C</sup> MEFs, compared to WT cells (<xref ref-type="fig" rid="F2">Figures 2A</xref> and <xref ref-type="supplementary-material" rid="SD1">S2</xref>). Protein levels for p21 and Mdm2, the products of two classical p53 target genes, appeared similar in <italic>Trp53</italic><sup>+/+</sup> and <italic>Trp53</italic><sup>+/Y217C</sup> MEFs, and were undetectable or markedly decreased in <italic>Trp53</italic><sup>Y217C/Y217C</sup> and <italic>Trp53</italic><sup>-/-</sup> MEFs (<xref ref-type="fig" rid="F2">Figures 2A</xref> and <xref ref-type="supplementary-material" rid="SD1">S2</xref>). Accordingly, p53<sup>Y217C</sup> appeared unable to transactivate the <italic>Cdkn1a/p21</italic> and <italic>Mdm2</italic> genes or to bind their promoters (<xref ref-type="fig" rid="F2">Figure 2B</xref>). The fractionation of cells before or after treatment with doxorubicin, a clastogenic drug, indicated that p53<sup>WT</sup> accumulated in the nucleoplasm and chromatin fractions in response to DNA damage, whereas p53<sup>Y217C</sup> appeared mostly cytoplasmic in both untreated and doxorubicin-treated cells, and undetectable or barely detectable in chromatin fractions (<xref ref-type="fig" rid="F2">Figures 2C</xref> and <xref ref-type="supplementary-material" rid="SD1">S3</xref>). Furthermore, when Nutlin-treated MEFs were analyzed by immunofluorescence, p53<sup>WT</sup> was only detected in nuclei, whereas p53<sup>Y217C</sup> could be observed in nuclear and cytoplasmic compartments (<xref ref-type="fig" rid="F2">Figure 2D</xref>). We next analyzed two well-known p53-mediated responses to DNA damage, i.e. cell cycle arrest in MEFs and apoptosis in thymocytes (<xref ref-type="bibr" rid="R44">Kastan et al., 1992</xref>; <xref ref-type="bibr" rid="R55">Lowe et al., 1993</xref>). WT MEFs exposed to increasing doses of ɣ-irradiation (3 Gy or 12 Gy) exhibited significant increases in G1/S ratios, whereas G1/S ratios were similar before or after irradiation in <italic>Trp53</italic><sup>Y217C/Y217C</sup> and <italic>Trp53</italic><sup>-/-</sup> MEFs (<xref ref-type="fig" rid="F2">Figures 2E</xref> and <xref ref-type="supplementary-material" rid="SD1">S4</xref>). Furthermore, thymocytes recovered from irradiated WT mice underwent a massive apoptotic response, with an almost three-fold increase in apoptotic cells after a 10 Gy irradiation. By contrast, no increase in apoptotic cells was observable upon irradiation in the thymi from <italic>Trp53</italic><sup>Y217C/Y217C</sup> mice, and apoptotic thymocytes were equally rare in irradiated <italic>Trp53</italic><sup>Y217C/Y217C</sup> and <italic>Trp</italic>53<sup>-/-</sup> mice (<xref ref-type="fig" rid="F2">Figures 2F</xref> and <xref ref-type="supplementary-material" rid="SD1">S5</xref>). Together, these results indicated that the p53<sup>Y217C</sup> mutation altered the abundance and intracellular distribution of the p53 protein, associated with a decrease in DNA-bound protein, and that p53<sup>Y217C</sup> had completely lost the ability to induce cell cycle arrest and apoptosis upon DNA damage.</p></sec><sec id="S5"><title>Increased chromosomal instability in <italic>Trp53</italic><sup>Y217C/Y217C</sup> cells</title><p id="P6">We next searched for evidence, at the cellular level, of potential dominant negative effect (DNE) or gain of function (GOF) for the p53<sup>Y217C</sup> mutant. Little if any difference in the transactivation of canonical p53 target genes was observed between WT, <italic>Trp53</italic><sup>+/Y217C</sup> and <italic>Trp53</italic><sup>+/-</sup> cells treated with Nutlin or Doxorubicin (<xref ref-type="supplementary-material" rid="SD1">Figure S6A</xref>), and <italic>Trp53</italic><sup>+/Y217C</sup> and <italic>Trp53</italic><sup>+/-</sup> cells exhibited similar cell cycle arrest or apoptotic responses to γ-irradiation (<xref ref-type="supplementary-material" rid="SD1">Figure S6B-C</xref>), suggesting little or no DNE in response to various stresses.</p><p id="P7">On the opposite, we obtained clear evidence of a GOF for the p53<sup>Y217C</sup> mutant. Two p53 mutants (p53<sup>G245D</sup> and p53<sup>R273H</sup>) were recently proposed to promote tumorigenesis by predisposing cells to chromosomal instability (<xref ref-type="bibr" rid="R96">Zhao et al., 2024</xref>), which led us to compare the frequency of chromosome rearrangements in WT, <italic>Trp53</italic><sup>Y217C/Y217C</sup> and <italic>Trp</italic>53<sup>-/-</sup> primary MEFs. We searched for chromosome breaks, radial chromosomes, or double-minute chromosomes (DMs) in preparations of MEFs treated with the anti-mitotic nocodazole for metaphase enrichment. The three categories of chromosome rearrangements were more frequently observed in <italic>Trp53</italic><sup>Y217C/Y217C</sup> MEFs than in <italic>Trp</italic>53<sup>-/-</sup> or WT cells (<xref ref-type="fig" rid="F2">Figure 2G</xref>), indicating a GOF that promotes chromosomal instability.</p></sec><sec id="S6"><title>Impact of p53<sup>Y217C</sup> on mouse development</title><p id="P8">We next determined the impact of the p53<sup>Y217C</sup> mutation <italic>in vivo</italic>, by comparing mouse cohorts generated from intercrosses of heterozygous <italic>Trp53</italic><sup>+/-</sup> or <italic>Trp53</italic><sup>+/Y217C</sup> mice resulting from ≥ 5 backcrosses to the C57BL6/J background. Intercrosses of <italic>Trp53</italic><sup>+/-</sup> mice are known to yield a reduced proportion of <italic>Trp53</italic><sup>-/-</sup> mice, that is mainly due to defects in neural tube closure causing exencephaly in a fraction of <italic>Trp53</italic><sup>-/-</sup> female embryos (<xref ref-type="bibr" rid="R4">Armstrong et al., 1995</xref>; <xref ref-type="bibr" rid="R71">Sah et al., 1995</xref>) and, to a lesser extent, to lung dysfunction affecting a fraction of <italic>Trp53</italic><sup>-/-</sup> neonates (<xref ref-type="bibr" rid="R79">Tateossian et al., 2015</xref>). At weaning (on the 21<sup>st</sup> day postpartum or P21), we observed one <italic>Trp53</italic><sup>-/-</sup> female mouse for 3.5 p53<sup>-/-</sup> males from <italic>Trp53</italic><sup>+/-</sup> intercrosses, an underrepresentation of females consistent with frequencies reported in earlier studies (<xref ref-type="bibr" rid="R4">Armstrong et al., 1995</xref>; <xref ref-type="bibr" rid="R71">Sah et al., 1995</xref>). Strikingly, the underrepresentation of weaned females was even more acute for <italic>Trp53</italic><sup>Y217C/Y217C</sup> mice, with only one <italic>Trp53</italic><sup>Y217C/Y217C</sup> female for 19 <italic>Trp53</italic><sup>Y217C/Y217C</sup> males from <italic>Trp53</italic><sup>+/Y217C</sup> intercrosses (<xref ref-type="fig" rid="F3">Figure 3A</xref>). We next analyzed <italic>Trp53</italic><sup>Y217C/Y217C</sup> embryos generated from heterozygous intercrosses or from heterozygous-homozygous (<italic>Trp53</italic><sup>+/Y217C</sup> x <italic>Trp53</italic><sup>Y217C/Y217C</sup>) crosses, at embryonic days E12.5-E16.5. An underrepresentation of <italic>Trp53</italic><sup>Y217C/Y217C</sup> female embryos was not observed, but 11/26 (42%) female embryos exhibited developmental abnormalities, including 10 with exencephaly, whereas all the male embryos appeared normal (<xref ref-type="fig" rid="F3">Figure 3B</xref>). Importantly, the frequency of <italic>Trp53</italic><sup>Y217C/Y217C</sup> female embryos with exencephaly (38.5%) was much higher than the reported frequency (0-8%) of <italic>Trp53</italic><sup>-/-</sup> female embryos with exencephaly of C57BL/6 x 129/Sv genetic background (<xref ref-type="bibr" rid="R18">Donehower et al., 1992</xref>; <xref ref-type="bibr" rid="R71">Sah et al., 1995</xref>), suggesting a stronger effect of the p53<sup>Y217C</sup> mutant on female embryonic development.</p><p id="P9">In <italic>Trp53</italic><sup>-/-</sup> female mice, exencephaly was previously correlated with stochastic aberrant X chromosome inactivation, with a decreased expression of <italic>Xist</italic> and an increase in bi-allelic expression of X-linked genes including <italic>Maob, Pls3</italic> and <italic>Usp9x</italic> (<xref ref-type="bibr" rid="R15">Delbridge et al., 2019</xref>). We prepared neurospheres from <italic>Trp53</italic><sup>+/+</sup>, <italic>Trp53</italic><sup>-/-</sup> and <italic>Trp53</italic><sup>Y217C/Y217C</sup> female embryos and quantified mRNAs for these genes in neurospheres. Compared to neurospheres from WT animals, <italic>Trp53</italic><sup>Y217C/Y217C</sup> and <italic>Trp53</italic><sup>-/-</sup> neurospheres exhibited an apparent decrease in <italic>Xist</italic> expression and significantly higher levels of <italic>Maob, Pls3</italic> and <italic>Usp9x</italic> (<xref ref-type="supplementary-material" rid="SD1">Figure S7</xref>). Thus, as for female <italic>Trp53</italic><sup>-/-</sup> mice, aberrant chromosome X inactivation may contribute to the underrepresentation of <italic>Trp53</italic><sup>Y217C/Y217C</sup> female mice. Of note however, defects in chromosome X inactivation did not appear more pronounced in <italic>Trp53</italic><sup>Y217C/Y217C</sup> neurospheres than in <italic>Trp53</italic><sup>-/-</sup> neurospheres.</p><p id="P10">To further analyze the impact of the p53<sup>Y217C</sup> mutation during development, we also determined its potential effect in embryos lacking Mdm2 or Mdm4, two major p53 regulators. The embryonic lethality resulting from Mdm2 or Mdm4 loss is rescued by a concomitant p53 deficiency (<xref ref-type="bibr" rid="R6">Bardot et al., 2015</xref>; <xref ref-type="bibr" rid="R24">Finch et al., 2002</xref>; <xref ref-type="bibr" rid="R41">Jones et al., 1995</xref>; <xref ref-type="bibr" rid="R59">Migliorini et al., 2002</xref>; <xref ref-type="bibr" rid="R60">Montes de Oca Luna et al., 1995</xref>; <xref ref-type="bibr" rid="R63">Parant et al., 2001</xref>). This provides a powerful assay for analyzing the functionality of p53 mutant alleles (<xref ref-type="bibr" rid="R6">Bardot et al., 2015</xref>; <xref ref-type="bibr" rid="R38">Iwakuma et al., 2004</xref>; <xref ref-type="bibr" rid="R56">Marine et al., 2006</xref>; <xref ref-type="bibr" rid="R81">Toledo et al., 2006</xref>). We identified <italic>Mdm2</italic><sup>-/-</sup> <italic>Trp53</italic><sup>Y217C/Y217C</sup> and <italic>Mdm4</italic><sup>-/-</sup> <italic>Trp53</italic><sup>Y217C/Y217C</sup> viable mice of both sexes, consistent with a major loss of canonical WT p53 activities in the p53<sup>Y217C</sup> mutant (<xref ref-type="supplementary-material" rid="SD1">Table S1</xref>). Of note, in these experiments we mated <italic>Mdm4</italic><sup>+/-</sup> <italic>Trp53</italic><sup>+/Y217C</sup> mice with <italic>Mdm4</italic><sup>+/-</sup> <italic>Trp53</italic><sup>Y217C/Y217C</sup> mice, or <italic>Mdm2</italic><sup>+/-</sup> <italic>Trp53</italic><sup>+/Y217C</sup> mice with either <italic>Mdm2</italic><sup>-/-</sup> <italic>Trp53</italic><sup>Y217C/Y217C</sup> or <italic>Mdm2</italic><sup>+/-</sup> <italic>Trp53</italic><sup>Y217C/Y217C</sup> animals, to analyze the progeny at weaning. No <italic>Trp53</italic><sup>Y217C/Y217C</sup> female mouse was recovered from these crosses, whereas 14 <italic>Trp53</italic><sup>Y217C</sup> <sup>/Y217C</sup> males were obtained, again demonstrating a striking deficit in <italic>Trp53</italic><sup>Y217C/Y217C</sup> females at weaning. Among animals lacking one or two copies of either <italic>Mdm2</italic> or <italic>Mdm4</italic>, we also observed a deficit in <italic>Trp53</italic><sup>Y217C/Y217C</sup> weaned females. However, the female to male ratio for <italic>Trp53</italic><sup>Y217C/Y217C</sup> animals appeared markedly increased in genetic backgrounds with <italic>Mdm4</italic> haploinsufficiency (4/15) or loss (1/6), but only marginally increased (if at all) in genetic backgrounds with <italic>Mdm2</italic> haploinsufficiency (1/11) or loss (1/11). This suggested that altering the levels of p53 inhibitors, particularly Mdm4, might improve the survival of <italic>Trp53</italic><sup>Y217C/Y217C</sup> females (<xref ref-type="supplementary-material" rid="SD1">Table S1</xref>).</p><p id="P11">The high frequency (42%) of abnormal <italic>Trp53</italic><sup>Y217C/Y217C</sup> female embryos at E12.5-E16.5 could only partially account for the acute deficit in <italic>Trp53</italic><sup>Y217C/Y217C</sup> females observed at weaning, suggesting either embryonic abnormalities undetectable macroscopically, or that a fraction of <italic>Trp53</italic><sup>Y217C/Y217C</sup> females died later in development or postpartum. We performed additional crosses to analyze female to male ratios at postpartum day 0 or 1 (P0-P1) and observed 20 females for 18 males for <italic>Trp53</italic><sup>+/+</sup> animals, but only five females for 22 males for <italic>Trp53</italic><sup>Y217C/Y217C</sup> animals (<xref ref-type="fig" rid="F3">Figure 3C</xref>). Furthermore, only one of these <italic>Trp53</italic><sup>Y217C/Y217C</sup> females reached weaning age, and the four other neonates died before P2. Altogether, these data led to conclude that the p53<sup>Y217C</sup> mutation caused female-specific developmental abnormalities at a higher penetrance than a null allele, leading to a perinatal (late embryonic or early postpartum) lethality for most homozygous mutant females.</p><p id="P12">Interestingly, we observed that <italic>Trp</italic>53<sup>Y217C/Y217C</sup> males were fertile and included them in some of our crosses to generate homozygous mutants at higher frequencies (<xref ref-type="fig" rid="F3">Figure 3B-C</xref>). By contrast, we were able to mate two <italic>Trp53</italic><sup>Y217C/Y217C</sup> adult females with a <italic>Trp53</italic><sup>+/Y217C</sup> male, and both got pregnant but had to be euthanized due to complications while giving birth. In both cases, extended labor (&gt; 24 hr) was the main sign of dystocia (<xref ref-type="supplementary-material" rid="SD1">Table S2</xref>). These observations suggest that, even for the rare <italic>Trp53</italic><sup>Y217C/Y217C</sup> females able to reach adulthood, the p53<sup>Y217C</sup> mutation caused pathological traits not observed in <italic>Trp53</italic><sup>-/-</sup> females, because the loss of p53 was not previously reported to cause dystocia (<xref ref-type="bibr" rid="R21">Embree-Ku and Boekelheide, 2002</xref>; <xref ref-type="bibr" rid="R29">Guimond et al., 1996</xref>; <xref ref-type="bibr" rid="R36">Hu et al., 2007</xref>). Together, our data indicated that the p53<sup>Y217C</sup> mutation not only abolished canonical p53 activities, but also conferred additional effects compromising female perinatal viability or parturition.</p></sec><sec id="S7"><title>Impact of p53<sup>Y217C</sup> on tumorigenesis</title><p id="P13">We next analyzed the impact of the p53<sup>Y217C</sup> mutation on the onset and spectrum of spontaneous tumors in mice. We first compared <italic>Trp53</italic><sup>+/Y217C</sup>, <italic>Trp53</italic><sup>+/-</sup> and <italic>Trp53</italic><sup>+/+</sup> mouse cohorts for 2 years. <italic>Trp53</italic><sup>+/Y217C</sup> and <italic>Trp53</italic><sup>+/-</sup> cohorts exhibited similar spontaneous tumor onset and spectrum, with most mice developing sarcomas during their second year of life (<xref ref-type="supplementary-material" rid="SD1">Figure S8</xref>). Thus, at least for tumors arising spontaneously, the p53<sup>Y217C</sup> mutant protein did not appear to exert a DNE over the wildtype p53 protein.</p><p id="P14">We next compared <italic>Trp53</italic><sup>Y217C/Y217C</sup> and <italic>Trp53</italic><sup>-/-</sup> mouse cohorts. Because of the difficulty to generate <italic>Trp53</italic><sup>Y217C/Y217C</sup> females, we restricted our comparison to males, to avoid potential biases that might result from different sex ratios. All <italic>Trp53</italic><sup>-/-</sup> mice are known to die in less than 1 year, from thymic lymphomas in most cases, or more rarely from sarcomas (<xref ref-type="bibr" rid="R18">Donehower et al., 1992</xref>; <xref ref-type="bibr" rid="R39">Jacks et al., 1994</xref>). <italic>Trp53</italic><sup>Y217C/Y217C</sup> males died faster than their <italic>Trp53</italic><sup>-/-</sup> counterparts: all the <italic>Trp53</italic><sup>Y217C/Y217C</sup> males were dead by the age of 7 months, whereas more than 20% of the <italic>Trp53</italic><sup>-/-</sup> males were still alive at that age (<xref ref-type="fig" rid="F4">Figure 4A</xref>). Furthermore, most <italic>Trp53</italic><sup>-/-</sup> and <italic>Trp53</italic><sup>Y217C/Y217C</sup> mice died from thymic lymphomas, but histological analysis of tumor organs revealed that the lymphomas in <italic>Trp53</italic><sup>Y217C/Y217C</sup> males were more aggressive and invasive, with sites of metastases notably including the lungs, spleen, liver or kidneys (<xref ref-type="fig" rid="F4">Figures 4B-C</xref> and <xref ref-type="supplementary-material" rid="SD1">S9</xref>). Thus, the p53<sup>Y217C</sup> mutation not only abolished canonical tumor suppressive activities but also apparently conferred oncogenic properties to the encoded protein. Consistent with this, when we performed an RNA-seq analysis of thymi from 8 weeks-old <italic>Trp53</italic><sup>+/+</sup>, <italic>Trp53</italic><sup>-/-</sup> and <italic>Trp53</italic><sup>Y217C/Y217C</sup> males, 81.5 % of the 717 differentially expressed genes indicated a loss of function (LOF) in the p53<sup>Y217C</sup> mutant, but genes suggesting a GOF or a separation of function (SOF) were also observed (<xref ref-type="supplementary-material" rid="SD1">Figure S10A</xref> and <xref ref-type="supplementary-material" rid="SD1">Table S3</xref>). Of note, among the differentially expressed genes corresponding to a LOF in the p53<sup>Y217C</sup> mutant were <italic>Bbc3/Puma, Cdkn1a/p21</italic> and <italic>Zmat3</italic> (<xref ref-type="supplementary-material" rid="SD1">Figure S10B</xref>), three p53-target genes known to play major roles in p53-mediated tumor suppression (<xref ref-type="bibr" rid="R13">Brennan et al., 2023</xref>).</p><p id="P15">We next performed a comparative analysis focusing on <italic>Trp53</italic><sup>Y217C/Y217C</sup> and <italic>Trp53</italic><sup>-/-</sup> thymi, which revealed 192 differentially expressed genes (<xref ref-type="fig" rid="F5">Figure 5A-B</xref> and <xref ref-type="supplementary-material" rid="SD1">Table S4</xref>). An analysis of these data with GOrilla, the Gene Ontology enRIchment anaLysis and visuaLizAtion tool (<xref ref-type="bibr" rid="R20">Eden et al., 2009</xref>), indicated that 141 of these genes were associated with at least one gene ontology (GO) term, and revealed a significant enrichment for genes associated with white blood cell chemotaxis/migration and inflammation (<xref ref-type="fig" rid="F5">Figures 5C</xref> and <xref ref-type="supplementary-material" rid="SD1">S11</xref>). Among these genes were notably <italic>Ccl17, Ccl9, Ccr3, Cxcl10, S100a8</italic> and <italic>S100a9</italic>, six genes associated each with 10-15 GO terms related to white blood cell behavior and inflammation (<xref ref-type="supplementary-material" rid="SD1">Table S5</xref>). We next used RT-qPCR to quantify the expression of these genes in thymi from 8 weeks-old <italic>Trp53</italic><sup>+/+</sup>, <italic>Trp53</italic><sup>Y217C/Y217C</sup> and <italic>Trp53</italic><sup>-/-</sup> male mice. Their expression was significantly increased in <italic>Trp53</italic><sup>Y217C/Y217C</sup> thymic cells compared to <italic>Trp53</italic><sup>-/-</sup>, or to both <italic>Trp53</italic><sup>+/+</sup> and <italic>Trp53</italic><sup>-/-</sup> cells, consistent with gain or separation of function (GOF/SOF) effects in the <italic>Trp53</italic><sup>Y217C</sup> mutant (<xref ref-type="fig" rid="F5">Figure 5D</xref>). We also compared the transcriptomes of <italic>Trp53</italic><sup>Y217C/Y217C</sup> and <italic>Trp53</italic><sup>-/-</sup> thymocytes by gene set enrichment analysis (<xref ref-type="bibr" rid="R78">Subramanian et al., 2005</xref>). We found 13 gene sets significantly enriched in <italic>Trp53</italic><sup>Y217C/Y217C</sup> cells with normalized enrichment scores (NES) &gt; 2, among which three (“antimicrobial peptides”, “chemokine receptors bind chemokines” and “defensins”) were related to immunity (<xref ref-type="fig" rid="F5">Figures 5E</xref> and <xref ref-type="supplementary-material" rid="SD1">S12A</xref>), consistent with an inflammatory response associated with the p53<sup>Y217C</sup> mutant. Other enriched gene sets notably included five sets (“electron transport chain”, “respiratory electron transport ATP synthesis by chemiosmotic coupling and heat production by uncoupling proteins”, “mitochondrial translation”, “respiratory electron transport” and “oxidative phosphorylation”) related to mitochondria function, and three sets (“deposition of new CENPA-containing nucleosomes at the centromere”, “arginine methyltransferases methylate histone arginines” and “PRC2 methylates histones and DNA”) related to chromatin plasticity (<xref ref-type="fig" rid="F5">Figures 5E</xref> and <xref ref-type="supplementary-material" rid="SD1">S12B-C</xref>). These gene sets, differentially expressed between <italic>Trp53</italic><sup>Y217C/Y217C</sup> and <italic>Trp53</italic><sup>-/-</sup> cells, might contribute to accelerated tumorigenesis in <italic>Trp53</italic><sup>Y217C/Y217C</sup> mice, given the reported impact of inflammation, metabolism changes and epigenetic plasticity on cancer evolution (<xref ref-type="bibr" rid="R22">Feinberg et al., 2006</xref>; <xref ref-type="bibr" rid="R28">Greten and Grivennikov, 2019</xref>; <xref ref-type="bibr" rid="R49">Kroemer and Pouyssegur, 2008</xref>). Furthermore, the hotspot mutants p53<sup>G245D</sup> or p53<sup>R273H</sup> were recently proposed to promote tumor progression by inducing non-canonical nuclear factor kappa light chain enhancer of activated B cell (NC-NF-κB) signaling (<xref ref-type="bibr" rid="R96">Zhao et al., 2024</xref>). In <italic>Trp53</italic><sup>Y217C/Y217C</sup> cells, one gene set related to NC-NF-κB (“Dectin 1-mediated non-canonical NF-κB signaling”) was significantly enriched and two other NF-κB-related gene sets were also potentially enriched (<xref ref-type="fig" rid="F5">Figure 5F</xref> and <xref ref-type="supplementary-material" rid="SD1">S13</xref>).</p></sec><sec id="S8"><title>Reducing inflammation may rescue a fraction of female <italic>Trp53</italic><sup>Y217C/Y217C</sup> embryos</title><p id="P16">Our data indicated that inflammation correlated with accelerated tumorigenesis in <italic>Trp53</italic><sup>Y217C/Y217C</sup> male mice. Interestingly, inflammation was previously proposed to promote neural tube defects or embryonic death in a few mouse models (<xref ref-type="bibr" rid="R51">Lian et al., 2004</xref>; <xref ref-type="bibr" rid="R58">McNairn et al., 2019</xref>; <xref ref-type="bibr" rid="R95">Zhao et al., 2013</xref>). Furthermore <italic>CD44</italic>, encoding a cell-surface glycoprotein that drives inflammation and cancer progression (<xref ref-type="bibr" rid="R76">Solier et al., 2023</xref>), was recently identified as a key gene for the diagnosis and early detection of open neural tube defects (<xref ref-type="bibr" rid="R43">Karthik et al., 2022</xref>). Together, these data led us to hypothesize that, at least in a fraction of <italic>Trp53</italic><sup>Y217C/Y217C</sup> females, neural tube defects might result from inflammation. To test this hypothesis, we mated <italic>Trp53</italic><sup>+/Y217C</sup> female mice with <italic>Trp53</italic><sup>Y217C/Y217C</sup> males, then administered supformin to pregnant females by oral gavage. Supformin (LCC-12), a potent inhibitor of the CD44-copper signaling pathway, was shown to reduce inflammation <italic>in vivo</italic> (<xref ref-type="bibr" rid="R76">Solier et al., 2023</xref>). Without any treatment, our previous crosses (<xref ref-type="fig" rid="F3">Figure 3</xref> and <xref ref-type="supplementary-material" rid="SD1">Table S1</xref>) collectively yielded a female to male ratio of 0.045 for <italic>Trp53</italic><sup>Y217C/Y217C</sup> weaned mice (f/m=5/111 [4+1+0+0]/[75+22+9+5]), significantly different from the ratio of 0.29 (f/m=8/28) for <italic>Trp53</italic><sup>-/-</sup> weaned animals. By contrast, in the progeny of supformin-treated pregnant mice we observed a five-fold increase in the female to male ratio for <italic>Trp53</italic><sup>Y217C/Y217C</sup> weaned animals, to reach a value of 0.23 (f/m=3/13) indistinguishable from the ratio in <italic>Trp53</italic><sup>-/-</sup> weaned animals from untreated mice (<xref ref-type="fig" rid="F5">Figure 5G</xref> and <xref ref-type="supplementary-material" rid="SD1">Table S6</xref>). This result suggests that reducing inflammation in developing <italic>Trp53</italic><sup>Y217C/Y217C</sup> female embryos may increase their viability.</p></sec></sec><sec id="S9" sec-type="discussion"><title>Discussion</title><p id="P17">In this report, we generated a mouse model with a <italic>Trp53</italic><sup>Y217C</sup> allele, the murine equivalent of the human hotspot mutant <italic>TP53</italic><sup>Y220C</sup>. The analysis of this mouse model indicated that the p53<sup>Y217C</sup> mutation leads to the loss of many canonical wildtype p53 activities, notably the capacity to transactivate target genes important for tumor suppression (e.g. <italic>Bbc3, Cdkn1a</italic> and <italic>Zmat3</italic>). The fact that p53<sup>Y217C</sup> can rescue the embryonic lethality caused by a deficiency in Mdm2 or Mdm4 is also consistent with a major loss of canonical wildtype p53 functions (LOF) in this mutant. These findings are consistent with the notion that hotspot p53 mutants cause a complete or near complete LOF (<xref ref-type="bibr" rid="R25">Funk et al., 2025</xref>).</p><p id="P18">In addition, our analyses provide evidence that the p53<sup>Y217C</sup> mutation exhibits oncogenic effects. The possibility that a mutant p53 might acquire oncogenic functions was first suggested over 30 years ago (<xref ref-type="bibr" rid="R17">Dittmer et al., 1993</xref>), but this notion became controversial in recent years. Indeed, studies of a few p53 mutants in human acute myeloid leukemia and a mouse model of B cell lymphoma indicated that their increased tumorigenicity might result from dominant-negative effects (DNE) rather than gain of function (GOF), and a recent study further suggested that the putative GOF of many p53 mutants would not be required to sustain the expansion of tumors (<xref ref-type="bibr" rid="R5">Aubrey et al., 2018</xref>; <xref ref-type="bibr" rid="R11">Boettcher et al., 2019</xref>; <xref ref-type="bibr" rid="R89">Wang et al., 2023</xref>). Here, however, we observed accelerated tumorigenesis in <italic>Trp53</italic><sup>Y217C/Y217C</sup> mice, but did not observe any evidence of DNE for spontaneous tumorigenesis in <italic>Trp53</italic><sup>+/Y217C</sup> animals. Importantly, the fact that p53<sup>Y217C</sup> did not exhibit a DNE over the WT protein is consistent with the report that Li-Fraumeni patients carrying an heterozygous <italic>TP53</italic><sup>Y220C</sup> mutation display a similar age of cancer onset than Li-Fraumeni patients with an heterozygous non-sense <italic>TP53</italic> mutation (<xref ref-type="bibr" rid="R91">Xu et al., 2014</xref>). Furthermore, our evidence of an oncogenic GOF leading to aggressive metastatic tumors in <italic>Trp53</italic><sup>Y217C/Y217C</sup> male mice is consistent with the oncogenic GOF attributed to p53<sup>Y220C</sup> in male patients with glioblastoma (<xref ref-type="bibr" rid="R69">Rockwell et al., 2021</xref>) or with experiments suggesting that p53<sup>Y220C</sup> expression in p53-null cells, or its overexpression in MCF-10A cells, may increase their migratory or invasive capacities (<xref ref-type="bibr" rid="R62">Pal et al., 2023</xref>; <xref ref-type="bibr" rid="R97">Zhou et al., 2022</xref>).</p><p id="P19">Our transcriptomic analyses suggested that the p53<sup>Y217C</sup> mutant might accelerate tumorigenesis by promoting inflammation, a hallmark of cancer (<xref ref-type="bibr" rid="R32">Hanahan, 2022</xref>) previously associated with a few other hotspot p53 mutants with oncogenic GOF (<xref ref-type="bibr" rid="R1">Agupitan et al., 2020</xref>; <xref ref-type="bibr" rid="R8">Behring et al., 2019</xref>; <xref ref-type="bibr" rid="R31">Ham et al., 2019</xref>; <xref ref-type="bibr" rid="R96">Zhao et al., 2024</xref>). Interestingly, the GSEA comparison of transcriptomes from <italic>Trp53</italic><sup>Y217C/Y217C</sup> and <italic>Trp</italic>53<sup>-/-</sup> male thymic cells indicated differences related to inflammation and chemokine signaling, but also to mitochondria function and chromatin plasticity, and a link between inflammation, mitochondrial copper and epigenetic plasticity was recently demonstrated (<xref ref-type="bibr" rid="R76">Solier et al., 2023</xref>). Furthermore, the p53<sup>G245D</sup> or p53<sup>R273H</sup> mutants were proposed to accelerate tumorigenesis by promoting a chromosomal instability that would activate NC-NF-kB signaling and promote tumor cell metastasis (<xref ref-type="bibr" rid="R96">Zhao et al., 2024</xref>). Here we observed increased chromosomal instability in <italic>Trp53</italic><sup>Y217C/Y217C</sup> fibroblasts, increased NC-NF-kB and inflammation-related signaling in <italic>Trp53</italic><sup>Y217C/Y217C</sup> thymocytes, and increased tumor metastasis in <italic>Trp53</italic><sup>Y217C/Y217C</sup> mice compared to their <italic>Trp53</italic><sup>-/-</sup> counterparts. These data suggest that similar mechanisms might underlie the oncogenic properties of the p53<sup>Y217C</sup>, p53<sup>G245D</sup> and p53<sup>R273H</sup> mutants.</p><p id="P20">A striking and unexpected effect of the p53<sup>Y217C</sup> mutation was its severe impact on the perinatal viability of female mice, which led to observe only four <italic>Trp53</italic><sup>Y217C/Y217C</sup> females for 75 <italic>Trp53</italic><sup>Y217C/Y217C</sup> males at weaning from heterozygous intercrosses, or five <italic>Trp53</italic><sup>Y217C/Y217C</sup> females for 111 <italic>Trp53</italic><sup>Y217C/Y217C</sup> males when all weaned animals from relevant crosses were considered. The perinatal lethality of <italic>Trp53</italic><sup>Y217C/Y217C</sup> females correlated with a high frequency (38.5%) of exencephalic females at E12.5-E16.5 embryonic ages. By comparison, the female to male ratio at weaning was 8/28 for <italic>Trp53</italic><sup>-/-</sup> mice, and only 0-8% of exencephalic female <italic>Trp53</italic><sup>-/-</sup> embryos were reported in similar genetic backgrounds (<xref ref-type="bibr" rid="R4">Armstrong et al., 1995</xref>; <xref ref-type="bibr" rid="R18">Donehower et al., 1992</xref>; <xref ref-type="bibr" rid="R71">Sah et al., 1995</xref>). These observations provide evidence of teratogenic effects for the p53<sup>Y217C</sup> mutant protein. Three other mouse p53 models were previously found to cause exencephaly at a higher frequency than a p53 null allele : <italic>Trp53</italic><sup>NLS1</sup>, with 3 mutations at residues 316-318 affecting a nuclear localization signal and leading to a predominantly cytoplasmic localization of p53<sup>NLS1</sup> in most cells (<xref ref-type="bibr" rid="R68">Regeling et al., 2011</xref>); <italic>Trp53</italic><sup>N236S</sup>, a mouse model of <italic>TP53</italic><sup>N239S</sup>, a recurrent but uncommon mutant in human cancers (<xref ref-type="bibr" rid="R94">Zhao et al., 2019</xref>); and <italic>Bim</italic><sup>+/-</sup> <italic>Trp53</italic><sup>-/-</sup> mice, combining p53 loss with an haploinsufficiency in the cytoplasmic proapoptotic regulator Bim/Bcl2l11 (<xref ref-type="bibr" rid="R15">Delbridge et al., 2019</xref>). The female-specific lethality of <italic>Trp53</italic><sup>N236S</sup> mice was proposed to result from increased <italic>Xist</italic> expression, whereas a decrease in <italic>Xist</italic> expression was observed in <italic>Bim</italic><sup>+/-</sup> <italic>Trp53</italic><sup>-/-</sup> mice, suggesting distinct causes for neural tube defects (<xref ref-type="bibr" rid="R15">Delbridge et al., 2019</xref>; <xref ref-type="bibr" rid="R94">Zhao et al., 2019</xref>). We observed decreased <italic>Xist</italic> expression and an increased expression of X-linked genes in neurospheres from <italic>Trp53</italic><sup>Y217C/Y217C</sup> females compared to WT females, whereas these genes were expressed at similar levels in neurospheres from <italic>Trp53</italic><sup>Y217C/Y217C</sup> and <italic>Trp53</italic><sup>-/-</sup> females. These results are not consistent with the mechanism proposed for exencephaly in the <italic>Trp53</italic><sup>N236S</sup> mouse model, but might rather reflect a p53 LOF in <italic>Trp53</italic><sup>Y217C/Y217C</sup> embryos. In addition, the analyses of the <italic>Trp53</italic><sup>NLS1</sup> and <italic>Bim</italic><sup>+/-</sup> <italic>Trp53</italic><sup>-/-</sup> mouse models make it tempting to speculate that, in female <italic>Trp53</italic><sup>Y217C/Y217C</sup> embryos, the abundance of p53<sup>Y217C</sup> in the cytoplasm might perturb mitochondria function (<xref ref-type="bibr" rid="R10">Blandino et al., 2020</xref>) to further promote neural tube closure defects. Consistent with this possibility, p53 mutant proteins accumulating in the cytoplasm were reported to inhibit autophagy (<xref ref-type="bibr" rid="R61">Morselli et al., 2008</xref>), a key determinant for mitochondrial integrity (<xref ref-type="bibr" rid="R67">Rambold and Lippincott-Schwartz, 2011</xref>), and autophagy impairment may promote neural tube defects (<xref ref-type="bibr" rid="R23">Fimia et al., 2007</xref>; <xref ref-type="bibr" rid="R92">Ye et al., 2020</xref>).</p><p id="P21">Importantly, our data suggest that common mechanisms might contribute to the oncogenic effects accelerating tumorigenesis in <italic>Trp53</italic><sup>Y217C/Y217C</sup> males and the teratogenic effects causing the perinatal lethality of many <italic>Trp53</italic><sup>Y217C/Y217C</sup> females. Indeed, the RNAseq analysis of male thymocytes indicated that inflammation likely promotes oncogenesis in <italic>Trp53</italic><sup>Y217C/Y217C</sup> males, and the administration of the anti-inflammatory drug supformin to pregnant mice increased the ratio of <italic>Trp53</italic><sup>Y217C/Y217C</sup> weaned females in their progeny. Thus, the low female/male ratio observed for <italic>Trp53</italic><sup>Y217C/Y217C</sup> weaned animals would likely result not only from aberrant X-chromosome inactivation in female embryos as in <italic>Trp53</italic><sup>-/-</sup> animals (<xref ref-type="bibr" rid="R15">Delbridge et al., 2019</xref>), but also from inflammation. Presumably, a higher level of chromosomal instability in <italic>Trp53</italic><sup>Y217C/Y217C</sup> cells might promote inflammation in <italic>Trp53</italic><sup>Y217C/Y217C</sup> embryos (<xref ref-type="bibr" rid="R70">Rodier et al., 2009</xref>), and this might be more detrimental to females because <italic>Trp53</italic><sup>Y217C/Y217C</sup> males would be protected by the anti-inflammatory effects of androgens (<xref ref-type="bibr" rid="R2">Ainslie et al., 2024</xref>; <xref ref-type="bibr" rid="R9">Bianchi, 2019</xref>; <xref ref-type="bibr" rid="R58">McNairn et al., 2019</xref>). Of note, we also observed that decreased Mdm4 levels increased the female/male ratio in <italic>Trp53</italic><sup>Y217C/Y217C</sup> weaned mice. Because MDM4 overexpression was shown to promote genome instability and inflammation in cells independently of p53 (<xref ref-type="bibr" rid="R14">Carrillo et al., 2015</xref>; <xref ref-type="bibr" rid="R53">Liu et al., 2024</xref>), it is tempting to speculate that, as for supformin-treated mice, the improved survival of <italic>Trp53</italic><sup>Y217C/Y217C</sup> female embryos in an Mdm4<sup>+/-</sup> background might result from decreased inflammation. Interestingly, in the offspring of human pregnancies at risk of early preterm delivery, an Interleukin-6 polymorphism was associated with a female-specific susceptibility to adverse neurodevelopmental outcome (<xref ref-type="bibr" rid="R83">Varner et al., 2020</xref>), suggesting that inflammation may also impact the development of human female embryos. Finally, our mating attempts with <italic>Trp53</italic><sup>Y217C/Y217C</sup> mice indicated that <italic>Trp53</italic><sup>Y217C/Y217C</sup> pregnant females exhibited dystocia, and parturition is considered to be a finely regulated inflammatory process (<xref ref-type="bibr" rid="R93">Zhang and Wei, 2021</xref>). Of note, dystocia was not observed in <italic>Trp53</italic><sup>-/-</sup> mice, but was previously reported in pregnant females with a combined deficiency of p53 and FasL (<xref ref-type="bibr" rid="R21">Embree-Ku and Boekelheide, 2002</xref>). The fact that <italic>Trp53</italic><sup>Y217C/Y217C</sup> females shared phenotypic traits with both <italic>Bim</italic><sup>+/-</sup> <italic>Trp53</italic><sup>-/-</sup> mice (neural tube defects) and <italic>FasL</italic><sup>-/-</sup> <italic>Trp53</italic><sup>-/-</sup> mice (dystocia) may seem relevant, because Bim and FasL are both regulators of apoptosis and autophagy that also regulate immune responses (<xref ref-type="bibr" rid="R75">Sionov et al., 2015</xref>; <xref ref-type="bibr" rid="R80">Taylor and Ng, 2018</xref>). Altogether, these data suggest that inflammation may cause accelerated tumorigenesis in <italic>Trp53</italic><sup>Y217C/Y217C</sup> male mice and contribute to promote neural tube defects in <italic>Trp53</italic><sup>Y217C/Y217C</sup> female embryos or dystocia in <italic>Trp53</italic><sup>Y217C/Y217C</sup> pregnant females (<xref ref-type="supplementary-material" rid="SD1">Table S7</xref>).</p><p id="P22">In conclusion, we generated a mouse model expressing p53<sup>Y217C</sup>, the murine equivalent of human p53<sup>Y220C</sup>, and its analysis revealed that the gain-of-function of a hotspot mutant p53 may not be limited to oncogenic effects. This is an important notion to consider given the ever-expanding functions ascribed to p53 (<xref ref-type="bibr" rid="R35">Hu, 2009</xref>; <xref ref-type="bibr" rid="R66">Rakotopare and Toledo, 2023</xref>; <xref ref-type="bibr" rid="R87">Voskarides and Giannopoulou, 2023</xref>; <xref ref-type="bibr" rid="R88">Vousden and Lane, 2007</xref>). In addition, our results unveiled the potential relevance of supformin in obstetrics, which deserves further investigation.</p></sec><sec id="S10" sec-type="materials | methods"><title>Materials and Methods</title><sec id="S11"><title>LSL-Y217C construct</title><p id="P23">We used mouse genomic <italic>Trp53</italic> DNA from previous constructs, containing a portion of intron 1 with a LoxP-Stop-LoxP (LSL) cassette (<xref ref-type="bibr" rid="R85">Ventura et al., 2007</xref>) in which the puromycin-resistance gene was replaced by a neomycin-resistance gene (<xref ref-type="bibr" rid="R73">Simeonova et al., 2013</xref>). The point mutation (A to G) encoding a Tyr to Cys substitution (TAT to TGT) at codon 217, together with a silent mutation nearby creating a Ban II restriction site, were introduced by PCR directed mutagenesis by using primers Y217C-F and Y217C-R (See <xref ref-type="supplementary-material" rid="SD1">Table S8</xref> for primer sequences). The resulting <italic>Trp53</italic><sup>LSL-Y217C</sup> targeting vector was fully sequenced before use.</p></sec><sec id="S12"><title>Targeting in ES Cells and Genotyping</title><p id="P24">129/SvJ embryonic stem (ES) cells were electroporated with the targeting construct linearized with Not I. Two recombinant clones, identified by long-range PCR and confirmed by internal PCR and Southern Blot, were injected into C57BL/6J blastocysts to generate chimeras, and germline transmission was verified by genotyping their offspring. <italic>In vivo</italic> excision of the LSL cassette was performed by breeding <italic>Trp53</italic><sup>+/LSL-Y217C</sup> male mice with females carrying the PGK-<italic>Cre</italic> transgene (<xref ref-type="bibr" rid="R50">Lallemand et al., 1998</xref>) and genotyping their offspring. The <italic>Trp53</italic><sup>Y217C</sup> (p53<sup>YC</sup>) mutation was routinely genotyped by PCR using primers c and d (<xref ref-type="fig" rid="F1">Figure 1</xref>, <xref ref-type="supplementary-material" rid="SD1">Table S8</xref>) followed by BanII digestion. Tumorigenesis studies were performed on mouse cohorts resulting from ≥ 5 generations of backcrosses with C57BL6/J mice. For all experiments, mice housing and treatment were conducted according to the Institutional Animal Care and Use Committee of the Institut Curie (approved project #03769.02).</p></sec><sec id="S13"><title>Cells and Cell Culture Reagents</title><p id="P25">Mouse embryonic fibroblasts (MEFs) isolated from 13.5-day embryos were cultured in a 5% CO2 and 3% O2 incubator, in DMEM GlutaMAX (Gibco), with 15% FBS (Biowest), 100 μM 2-mercaptoethanol (Millipore), 0.01 mM Non-Essential Amino-Acids, and penicillin/streptomycin (Gibco) for ≤ 6 passages. Cells were irradiated with a Cs γ-irradiator or treated for 24 hr with 10 μM Nutlin 3a (Sigma-Aldrich) or 1 μM Doxorubicin (Sigma-Aldrich). Neurospheres were prepared by isolating neural stem/progenitor cells (NPCs) from the lateral and median ganglionic eminences of E14.5 embryos. NPCs were cultured in a 5% CO2 incubator, in DMEM/F12 medium (with L-Glutamine, Invitrogen) supplemented with 1% B-27 (Invitrogen), 1% N2 (Invitrogen), 0.3% glucose (Invitrogen), 25 μg/ml insulin (Sigma-Aldrich), 20 ng/ml EGF (PeproTech), 10 ng/ml bFGF (PeproTech) and penicillin/streptomycin (Gibco). Neurospheres were dissociated once a week by Accutase treatment and mechanically, then seeded at 10<sup>6</sup> cells per 6 cm diameter dish.</p></sec><sec id="S14"><title>Quantitative RT-PCR</title><p id="P26">Total RNA, extracted using NucleoSpin RNA II (Macherey-Nagel), was reverse transcribed using SuperScript IV (Invitrogen). Real-time quantitative PCRs were performed as previously described (<xref ref-type="bibr" rid="R74">Simeonova et al., 2012</xref>), on an ABI PRISM 7500 using Power SYBR Green (Applied Biosystems). Primer sequences are reported in <xref ref-type="supplementary-material" rid="SD1">Table S8</xref>.</p></sec><sec id="S15"><title>Western Blots</title><p id="P27">Cells were lysed in RIPA buffer (50 mM Tris-HCl pH 8, 150 mM NaCl, 5 mM EDTA, 0.5% deoxycholic acid, 0.1% SDS, 1% NP-40) supplemented with Protease inhibitors cocktail (Roche) and 1 mM PMSF (Sigma). Whole-cell extracts were sonicated three times for 10 s and centrifuged at 13 000 rpm for 30 min to remove cell debris. Protein lysate concentration was determined by BCA assay (Thermo Scientific) and 30 μg of each lysate was fractionated by SDS–PAGE on a 4-12% polyacrylamide gel and transferred onto polyvynilidene difluoride (PVDF) membranes (Amersham). Membranes were incubated with antibodies raised against Mdm2 (MDM2-4B2, Abcam, 1/500), p53 (CM-5, Novocastra, 1/2000), p21 (F5, Santa Cruz Biotechnology, 1/200) and actin (actin-HRP sc47778, Santa Cruz Biotechnology, 1/5000). Chemiluminescence revelation of western blots was achieved with the SuperSignal West Dura (Perbio).</p></sec><sec id="S16"><title>ChIP Assay</title><p id="P28">ChIP analysis was performed as previously described (<xref ref-type="bibr" rid="R73">Simeonova et al., 2013</xref>). p53-DNA complexes were immunoprecipitated from total extracts by using 50 μg of a polyclonal antibody against p53 (FL-393, Santa Cruz Biotechnology) and 300 μg of sonicated chromatin. Rabbit IgG (Abcam) was used for control precipitation. Quantitative PCR was performed on ABI PRISM 7500. Primer sequences are reported in <xref ref-type="supplementary-material" rid="SD1">Table S8</xref>.</p></sec><sec id="S17"><title>Cell Fractionation Assay</title><p id="P29">Cells were lysed in hypotonic lysis buffer (10 mM Tris pH 7.5, 10 mM NaCl, 3 mM Mgcl2, 0.3% NP-40, 10% glycerol) on ice for 10 min, then centrifuged at 4°C for 3 min at 1000g. The supernatant was recovered as the cytoplasmic fraction, and the pellet was incubated in a modified Wuarin-Schibler buffer (10 mM Tris-HCl pH 7.0, 4 mM EDTA, 0.3 M NaCl, 1 M urea, 1% NP-40) on ice for 5 min, vortexed, incubated on ice for 10 min, then centrifuged at 4°C for 3 min at 1000g. The supernatant was recovered as the nucleoplasmic fraction, and the pellet was washed, then incubated in a nuclear lysis buffer (20 mM Tris pH 7.5, 150 mM KCl, 3 mM MgCl2, 0.3% NP-40, 10% glycerol) on ice for 5 min, sonicated, then centrifuged at 13000 rpm at 4°C and the supernatant was recovered as the chromatin fraction. All buffers were supplemented with Protease inhibitors cocktail (Roche). Cellular fractions were analyzed by western blots with antibodies against p53 (AF-1355, R&amp;D systems, 1/600), Tubulin (ab15568, Abcam, 1/1000), Nup98 (ab50610, Abcam, 1/1000) and histone H3 (ab1791, Abcam, 1/1000). Chemiluminescence revelation was achieved with SuperSignal West Pico or Femto (Thermoscientific) and analyzed with a ChemiDoc imaging system (Bio-Rad).</p></sec><sec id="S18"><title>Immunofluorescence</title><p id="P30">MEFs were cultured on collagen-coated coverslips, treated with 10 μM Nutlin 3a (Sigma-Aldrich) for 24 hr and analyzed. Coverslips were stained with rabbit anti-p53 FL-393 (Santa Cruz Biotechnology, 1/50), mouse anti-actin primary antibody and with Alexa Fluor 647 anti-Rabbit and Alexa Fluor 488 anti-Mouse secondary antibodies (Molecular Probes). DNA was counterstained with DAPI. Images were captured on an epifluorescence microscope using equal exposure times for all images for each fluor.</p></sec><sec id="S19"><title>Cell-Cycle Assay</title><p id="P31">Log phase cells were irradiated at room temperature (RT) with a Cs γ-irradiator at doses of 3 or 12 Gy, incubated for 24 hr, then pulse labeled for 1 hr with BrdU (10 μM), fixed in 70% ethanol, double stained with FITC anti-BrdU and propidium iodide, and analyzed by flow cytometry with a BD Biosciences FACSort and the FlowJo software.</p></sec><sec id="S20"><title>Apoptosis Assay</title><p id="P32">Six to eight weeks-old mice were left untreated or submitted to 10 Gy whole-body ɣ-irradiation. Mice were sacrificed 4 hr later and thymi were extracted. Thymocytes were recovered by filtration through a 70 μm smash, stained with Annexin V-FITC Apoptosis detection kit (Abcam) and propidium iodide, then analyzed with a LSRII FACS machine. Data were analyzed using Flowjo software.</p></sec><sec id="S21"><title>Metaphase spread preparation and analysis</title><p id="P33">Primary MEFs (at passage 4 for all genotypes) were treated with 0.1 mM nocodazole for 3 h to arrest cells in metaphase, then submitted to hypotonic shock (75 mM KCl), fixed in a (3:1) ethanol/acetic acid solution, dropped onto glass slides, then air-dried slides were stained with Giemsa to score for chromosome aberrations. Images were acquired using a Zeiss Axiophot (X63) microscope.</p></sec><sec id="S22"><title>Histology</title><p id="P34">Organs were fixed in formol 4% for 24 hr, then ethanol 70%, and embedded in paraffin wax. Serial sections of 3 μm were stained as described (<xref ref-type="bibr" rid="R73">Simeonova et al., 2013</xref>), with hematoxylin and eosin using standard procedures.</p></sec><sec id="S23"><title>RNA-Seq analysis</title><p id="P35">Total RNA was extracted from the thymi of 8 weeks-old asymptomatic male mice using nucleospin RNA II (Macherey-Nagel). The quality of RNA was checked with Bioanalyzer Agilent 2100 and RNAs with a RIN (RNA integrity number) ≥ 7 were retained for further analysis. RNA was depleted from ribosomal RNA, then converted into cDNA libraries using a TruSeq Stranded Total Library preparation kit (Illumina). Paired-end sequencing was performed on an Illumina MiSeq platform. Reads were mapped to the mouse genome version GRCm38 and counted on gene annotation gencode.vM18 with featureCounts (<xref ref-type="bibr" rid="R52">Liao et al., 2014</xref>). Differentially expressed genes with an adjusted p-value &lt; 0.05 were identified using the DESeq2 R package (<xref ref-type="bibr" rid="R54">Love et al., 2014</xref>).</p></sec><sec id="S24"><title>Gene Ontology analysis</title><p id="P36">Gene ontology analysis of differentially expressed genes was performed by using the GOrilla (Technion) software as previously described (<xref ref-type="bibr" rid="R65">Rakotopare et al., 2023</xref>). Enrichment analyses were carried out by comparing the list of 192 differentially expressed genes between <italic>Trp53</italic><sup>Y217C/Y217C</sup> and <italic>Trp53</italic><sup>-/-</sup> thymi to the full list of genes (background), with ontology searches for biological processes and default <italic>P</italic>-value settings (10<sup>−3</sup>).</p></sec><sec id="S25"><title>Gene set enrichment analysis</title><p id="P37">Gene set enrichment analysis was performed by using the GSEA software with canonical pathway gene sets from the Mouse Molecular Signature Database (MSigDB) (<xref ref-type="bibr" rid="R78">Subramanian et al., 2005</xref>). Gene sets with a false discovery rate (FDR) q-value &lt; 0.25 were regarded as potentially relevant. The best candidates, with an FDR q-value &lt; 0.01, exhibited normalized enrichment scores (NES) &gt; 1.91 and nominal (NOM) P-values &lt;0.003.</p></sec><sec id="S26"><title>Oral gavage of pregnant females</title><p id="P38"><italic>Trp53</italic><sup>+/Y217C</sup> female mice were mated with <italic>Trp53</italic><sup>Y217C/Y217C</sup> males, then mice with a vaginal plug on the next day were separated from males and weighted every other day to confirm pregnancy. On the 10<sup>th</sup> and 11<sup>th</sup> days post-coitum, pregnant mice received 5 mg/kg of supformin (in a PBS solution) by oral gavage with flexible gauge feeding tubes, then their pups were genotyped at weaning.</p></sec><sec id="S27"><title>Statistical analyses</title><p id="P39">Unless noted otherwise, we used a Student’s <italic>t</italic> test to analyze differences between two groups of values. For the proportions of mice at weaning, the observed mouse count was compared to the expected count according to Mendel’s distribution and a Chi-square (χ<sup>2</sup>) test, and a Fischer’s test was applied to compare frequencies of mutant females or female to male ratios. Fischer’s tests were also used to analyze frequencies of chromosome rearrangements in fibroblasts. Survival curves were analyzed with log-rank Mantel-Cox tests. Analyses were performed by using GraphPad Prism, and values of P ≤ 0.05 were considered significant.</p></sec></sec><sec sec-type="supplementary-material" id="SM"><title>Supplementary Material</title><supplementary-material content-type="local-data" id="SD1"><label>Supplementary Materials</label><media xlink:href="EMS199093-supplement-Supplementary_Materials.pdf" mimetype="application" mime-subtype="pdf" id="d14aAcEbB" position="anchor"/></supplementary-material></sec></body><back><ack id="S28"><title>Acknowledgments</title><p>This project was supported by grants attributed to F.T., from the Ligue Nationale Contre le Cancer, the Fondation ARC pour la recherche sur le Cancer and the Gefluc. S.J., E.E. and J.R. were PhD fellows of the Ministère de la Recherche, supervised by F.T. (S.J., J.R.) or B.B. (E.E.). S.J. and E.E. received additional support from the Fondation ARC. M.G. was paid by European Research Council 875532-Prostator-ERC-2019-PoC attributed to A.M. For some experiments, S.J. and V.V. received technical assistance from C. Bouyer and R. Bourimi. We thank the following members of the Institut Curie platforms: I. Grandjean, H. Gautier, C. Daviaud, M. Garcia, D. Andreau, M. Verlhac and A. Fosse (animal facility); S. Baulande and S. Lameiras (NGS); M. Huerre, A. Nicolas and R. Leclere (histopathology); Z. Maciorowski, A. Viguier and S. Grondin (flow cytometry).</p></ack><sec id="S29" sec-type="data-availability"><title>Data availability</title><p id="P40">RNA sequencing data have been deposited in the Gene Expression Omnibus (GEO) under the accession code GSE248936. All other data are available within the article and its supplementary information.</p></sec><fn-group><fn fn-type="con" id="FN1"><p id="P41"><bold>Author Contributions</bold></p><p id="P42">Conceptualization: F.T.; investigation: S.J., E.E., J.R., I.S, V.L., V.V., M.L., A.F., B.B., F.T.; formal analysis: M.G., B.B., F.T.; resources: T.C., R.R., A.M.; supervision, writing and visualization: F.T., B.B; project administration and funding acquisition: F.T.</p></fn><fn fn-type="conflict" id="FN2"><p id="P43"><bold>Declaration of interests</bold></p><p id="P44">The authors declare no competing financial interests.</p></fn></fn-group><ref-list><ref id="R1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Agupitan</surname><given-names>AD</given-names></name><name><surname>Neeson</surname><given-names>P</given-names></name><name><surname>Williams</surname><given-names>S</given-names></name><name><surname>Howitt</surname><given-names>J</given-names></name><name><surname>Haupt</surname><given-names>S</given-names></name><name><surname>Haupt</surname><given-names>Y</given-names></name></person-group><article-title>P53: A Guardian of Immunity Becomes Its Saboteur through Mutation</article-title><source>Int J Mol Sci</source><year>2020</year><volume>21</volume><fpage>3452</fpage><pub-id pub-id-type="pmcid">PMC7278985</pub-id><pub-id pub-id-type="pmid">32414156</pub-id><pub-id pub-id-type="doi">10.3390/ijms21103452</pub-id></element-citation></ref><ref id="R2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ainslie</surname><given-names>RJ</given-names></name><name><surname>Simitsidellis</surname><given-names>I</given-names></name><name><surname>Kirkwood</surname><given-names>PM</given-names></name><name><surname>Gibson</surname><given-names>DA</given-names></name></person-group><article-title>RISING STARS: Androgens and immune cell function</article-title><source>J Endocrinol</source><year>2024</year><volume>261</volume><elocation-id>e230398</elocation-id><pub-id pub-id-type="pmcid">PMC11103679</pub-id><pub-id pub-id-type="pmid">38579776</pub-id><pub-id pub-id-type="doi">10.1530/JOE-23-0398</pub-id></element-citation></ref><ref id="R3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Amelio</surname><given-names>I</given-names></name><name><surname>Melino</surname><given-names>G</given-names></name></person-group><article-title>Context is everything: extrinsic signalling and gain-of-function p53 mutants</article-title><source>Cell Death Discov</source><year>2020</year><volume>6</volume><fpage>16</fpage><pub-id pub-id-type="pmcid">PMC7090043</pub-id><pub-id pub-id-type="pmid">32218993</pub-id><pub-id pub-id-type="doi">10.1038/s41420-020-0251-x</pub-id></element-citation></ref><ref id="R4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Armstrong</surname><given-names>JF</given-names></name><name><surname>Kaufman</surname><given-names>MH</given-names></name><name><surname>Harrison</surname><given-names>DJ</given-names></name><name><surname>Clarke</surname><given-names>AR</given-names></name></person-group><article-title>High-frequency developmental abnormalities in p53-deficient mice</article-title><source>Curr Biol</source><year>1995</year><volume>5</volume><fpage>931</fpage><lpage>936</lpage><pub-id pub-id-type="pmid">7583151</pub-id></element-citation></ref><ref id="R5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aubrey</surname><given-names>BJ</given-names></name><name><surname>Janic</surname><given-names>A</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Chang</surname><given-names>C</given-names></name><name><surname>Lieschke</surname><given-names>EC</given-names></name><name><surname>Diepstraten</surname><given-names>ST</given-names></name><name><surname>Kueh</surname><given-names>AJ</given-names></name><name><surname>Bernardini</surname><given-names>JP</given-names></name><name><surname>Dewson</surname><given-names>G</given-names></name><name><surname>O’Reilly</surname><given-names>LA</given-names></name><name><surname>Whitehead</surname><given-names>L</given-names></name><etal/></person-group><article-title>Mutant TRP53 exerts a target gene-selective dominant-negative effect to drive tumor development</article-title><source>Genes Dev</source><year>2018</year><volume>32</volume><fpage>1420</fpage><lpage>1429</lpage><pub-id pub-id-type="pmcid">PMC6217734</pub-id><pub-id pub-id-type="pmid">30366906</pub-id><pub-id pub-id-type="doi">10.1101/gad.314286.118</pub-id></element-citation></ref><ref id="R6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bardot</surname><given-names>B</given-names></name><name><surname>Bouarich-Bourimi</surname><given-names>R</given-names></name><name><surname>Leemput</surname><given-names>J</given-names></name><name><surname>Lejour</surname><given-names>V</given-names></name><name><surname>Hamon</surname><given-names>A</given-names></name><name><surname>Plancke</surname><given-names>L</given-names></name><name><surname>Jochemsen</surname><given-names>AG</given-names></name><name><surname>Simeonova</surname><given-names>I</given-names></name><name><surname>Fang</surname><given-names>M</given-names></name><name><surname>Toledo</surname><given-names>F</given-names></name></person-group><article-title>Mice engineered for an obligatory Mdm4 exon skipping express higher levels of the Mdm4-S isoform but exhibit increased p53 activity</article-title><source>Oncogene</source><year>2015</year><volume>34</volume><fpage>2943</fpage><lpage>2948</lpage><pub-id pub-id-type="pmid">25088193</pub-id></element-citation></ref><ref id="R7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beckerman</surname><given-names>R</given-names></name><name><surname>Prives</surname><given-names>C</given-names></name></person-group><article-title>Transcriptional regulation by p53</article-title><source>Cold Spring Harb Perspect Biol</source><year>2010</year><volume>2</volume><elocation-id>a000935</elocation-id><pub-id pub-id-type="pmcid">PMC2908772</pub-id><pub-id pub-id-type="pmid">20679336</pub-id><pub-id pub-id-type="doi">10.1101/cshperspect.a000935</pub-id></element-citation></ref><ref id="R8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Behring</surname><given-names>M</given-names></name><name><surname>Vazquez</surname><given-names>AI</given-names></name><name><surname>Cui</surname><given-names>X</given-names></name><name><surname>Irvin</surname><given-names>MR</given-names></name><name><surname>Ojesina</surname><given-names>AI</given-names></name><name><surname>Agarwal</surname><given-names>S</given-names></name><name><surname>Manne</surname><given-names>U</given-names></name><name><surname>Shrestha</surname><given-names>S</given-names></name></person-group><article-title>Gain of function in somatic <italic>TP53</italic> mutations is associated with immune-rich breast tumors and changes in tumor-associated macrophages</article-title><source>Molec Genet Genomic Med</source><year>2019</year><volume>7</volume><elocation-id>e1001</elocation-id><pub-id pub-id-type="pmcid">PMC6900370</pub-id><pub-id pub-id-type="pmid">31637877</pub-id><pub-id pub-id-type="doi">10.1002/mgg3.1001</pub-id></element-citation></ref><ref id="R9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bianchi</surname><given-names>VE</given-names></name></person-group><article-title>The Anti-Inflammatory Effects of Testosterone</article-title><source>J Endocr Soc</source><year>2019</year><volume>3</volume><fpage>91</fpage><lpage>107</lpage><pub-id pub-id-type="pmcid">PMC6299269</pub-id><pub-id pub-id-type="pmid">30582096</pub-id><pub-id pub-id-type="doi">10.1210/js.2018-00186</pub-id></element-citation></ref><ref id="R10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blandino</surname><given-names>G</given-names></name><name><surname>Valenti</surname><given-names>F</given-names></name><name><surname>Sacconi</surname><given-names>A</given-names></name><name><surname>Di Agostino</surname><given-names>S</given-names></name></person-group><article-title>Wild type- and mutant p53 proteins in mitochondrial dysfunction: emerging insights in cancer disease</article-title><source>Semin Cell Dev Biol</source><year>2020</year><volume>98</volume><fpage>105</fpage><lpage>117</lpage><pub-id pub-id-type="pmid">31112799</pub-id></element-citation></ref><ref id="R11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boettcher</surname><given-names>S</given-names></name><name><surname>Miller</surname><given-names>PG</given-names></name><name><surname>Sharma</surname><given-names>R</given-names></name><name><surname>McConkey</surname><given-names>M</given-names></name><name><surname>Leventhal</surname><given-names>M</given-names></name><name><surname>Krivtsov</surname><given-names>AV</given-names></name><name><surname>Giacomelli</surname><given-names>AO</given-names></name><name><surname>Wong</surname><given-names>W</given-names></name><name><surname>Kim</surname><given-names>J</given-names></name><name><surname>Chao</surname><given-names>S</given-names></name><name><surname>Kurppa</surname><given-names>KJ</given-names></name><etal/></person-group><article-title>A dominant-negative effect drives selection of TP53 missense mutations in myeloid malignancies</article-title><source>Science</source><year>2019</year><volume>365</volume><fpage>599</fpage><lpage>604</lpage><pub-id pub-id-type="pmcid">PMC7327437</pub-id><pub-id pub-id-type="pmid">31395785</pub-id><pub-id pub-id-type="doi">10.1126/science.aax3649</pub-id></element-citation></ref><ref id="R12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bouaoun</surname><given-names>L</given-names></name><name><surname>Sonkin</surname><given-names>D</given-names></name><name><surname>Ardin</surname><given-names>M</given-names></name><name><surname>Hollstein</surname><given-names>M</given-names></name><name><surname>Byrnes</surname><given-names>G</given-names></name><name><surname>Zavadil</surname><given-names>J</given-names></name><name><surname>Olivier</surname><given-names>M</given-names></name></person-group><article-title>TP53 Variations in Human Cancers: New Lessons from the IARC TP53 Database and Genomics Data</article-title><source>Hum Mutat</source><year>2016</year><volume>37</volume><fpage>865</fpage><lpage>876</lpage><pub-id pub-id-type="pmid">27328919</pub-id></element-citation></ref><ref id="R13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brennan</surname><given-names>MS</given-names></name><name><surname>Brinkmann</surname><given-names>K</given-names></name><name><surname>Romero Sola</surname><given-names>G</given-names></name><name><surname>Healey</surname><given-names>G</given-names></name><name><surname>Gibson</surname><given-names>L</given-names></name><name><surname>Gangoda</surname><given-names>L</given-names></name><name><surname>Potts</surname><given-names>MA</given-names></name><name><surname>Lieschke</surname><given-names>E</given-names></name><name><surname>Wilcox</surname><given-names>S</given-names></name><name><surname>Strasser</surname><given-names>A</given-names></name><name><surname>Herold</surname><given-names>MJ</given-names></name><etal/></person-group><article-title>Combined absence of TRP53 target genes ZMAT3, PUMA and p21 cause a high incidence of cancer in mice</article-title><source>Cell Death Differ</source><year>2023</year><pub-id pub-id-type="pmcid">PMC10850490</pub-id><pub-id pub-id-type="pmid">38110554</pub-id><pub-id pub-id-type="doi">10.1038/s41418-023-01250-w</pub-id></element-citation></ref><ref id="R14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carrillo</surname><given-names>AM</given-names></name><name><surname>Bouska</surname><given-names>A</given-names></name><name><surname>Arrate</surname><given-names>MP</given-names></name><name><surname>Eischen</surname><given-names>CM</given-names></name></person-group><article-title>Mdmx promotes genomic instability independent of p53 and Mdm2</article-title><source>Oncogene</source><year>2015</year><volume>34</volume><fpage>846</fpage><lpage>856</lpage><pub-id pub-id-type="pmcid">PMC4160436</pub-id><pub-id pub-id-type="pmid">24608433</pub-id><pub-id pub-id-type="doi">10.1038/onc.2014.27</pub-id></element-citation></ref><ref id="R15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Delbridge</surname><given-names>ARD</given-names></name><name><surname>Kueh</surname><given-names>AJ</given-names></name><name><surname>Ke</surname><given-names>F</given-names></name><name><surname>Zamudio</surname><given-names>NM</given-names></name><name><surname>El-Saafin</surname><given-names>F</given-names></name><name><surname>Jansz</surname><given-names>N</given-names></name><name><surname>Wang</surname><given-names>G-Y</given-names></name><name><surname>Iminitoff</surname><given-names>M</given-names></name><name><surname>Beck</surname><given-names>T</given-names></name><name><surname>Haupt</surname><given-names>S</given-names></name><name><surname>Hu</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Loss of p53 Causes Stochastic Aberrant X-Chromosome Inactivation and Female-Specific Neural Tube Defects</article-title><source>Cell Rep</source><year>2019</year><volume>27</volume><fpage>442</fpage><lpage>454</lpage><elocation-id>e5</elocation-id><pub-id pub-id-type="pmid">30970248</pub-id></element-citation></ref><ref id="R16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dibra</surname><given-names>D</given-names></name><name><surname>Xiong</surname><given-names>S</given-names></name><name><surname>Moyer</surname><given-names>SM</given-names></name><name><surname>El-Naggar</surname><given-names>AK</given-names></name><name><surname>Qi</surname><given-names>Y</given-names></name><name><surname>Su</surname><given-names>X</given-names></name><name><surname>Kong</surname><given-names>EK</given-names></name><name><surname>Korkut</surname><given-names>A</given-names></name><name><surname>Lozano</surname><given-names>G</given-names></name></person-group><article-title>Mutant p53 protects triple-negative breast adenocarcinomas from ferroptosis in vivo</article-title><source>Sci Adv</source><year>2024</year><volume>10</volume><elocation-id>eadk1835</elocation-id><pub-id pub-id-type="pmcid">PMC10866549</pub-id><pub-id pub-id-type="pmid">38354236</pub-id><pub-id pub-id-type="doi">10.1126/sciadv.adk1835</pub-id></element-citation></ref><ref id="R17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dittmer</surname><given-names>D</given-names></name><name><surname>Pati</surname><given-names>S</given-names></name><name><surname>Zambetti</surname><given-names>G</given-names></name><name><surname>Chu</surname><given-names>S</given-names></name><name><surname>Teresky</surname><given-names>AK</given-names></name><name><surname>Moore</surname><given-names>M</given-names></name><name><surname>Finlay</surname><given-names>C</given-names></name><name><surname>Levine</surname><given-names>AJ</given-names></name></person-group><article-title>Gain of function mutations in p53</article-title><source>Nat Genet</source><year>1993</year><volume>4</volume><fpage>42</fpage><lpage>46</lpage><pub-id pub-id-type="pmid">8099841</pub-id></element-citation></ref><ref id="R18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Donehower</surname><given-names>LA</given-names></name><name><surname>Harvey</surname><given-names>M</given-names></name><name><surname>Slagle</surname><given-names>BL</given-names></name><name><surname>McArthur</surname><given-names>MJ</given-names></name><name><surname>Montgomery</surname><given-names>CA</given-names></name><name><surname>Butel</surname><given-names>JS</given-names></name><name><surname>Bradley</surname><given-names>A</given-names></name></person-group><article-title>Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours</article-title><source>Nature</source><year>1992</year><volume>356</volume><fpage>215</fpage><lpage>221</lpage><pub-id pub-id-type="pmid">1552940</pub-id></element-citation></ref><ref id="R19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dumbrava</surname><given-names>E</given-names></name><name><surname>Johnson</surname><given-names>M</given-names></name><name><surname>Tolcher</surname><given-names>A</given-names></name><name><surname>Shapiro</surname><given-names>G</given-names></name><name><surname>Thompson</surname><given-names>J</given-names></name><name><surname>El-Khoueiry</surname><given-names>A</given-names></name><name><surname>Vandross</surname><given-names>A</given-names></name><name><surname>Kummar</surname><given-names>S</given-names></name><name><surname>Parikh</surname><given-names>A</given-names></name><name><surname>Munster</surname><given-names>P</given-names></name><name><surname>Daly</surname><given-names>E</given-names></name><etal/></person-group><article-title>First-in-human study of PC14586, a small molecule structural corrector of Y220C mutant p53, in patients with advanced solid tumors harboring a TP53 Y220C mutation</article-title><source>J Clin Oncol</source><year>2022</year><volume>40</volume><issue>suppl 3003</issue><pub-id pub-id-type="doi">10.1200/JCO.2022.40.16_suppl.3003</pub-id></element-citation></ref><ref id="R20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eden</surname><given-names>E</given-names></name><name><surname>Navon</surname><given-names>R</given-names></name><name><surname>Steinfeld</surname><given-names>I</given-names></name><name><surname>Lipson</surname><given-names>D</given-names></name><name><surname>Yakhini</surname><given-names>Z</given-names></name></person-group><article-title>GOrilla: a tool for discovery and visualization of enriched GO terms in ranked gene lists</article-title><source>BMC Bioinformatics</source><year>2009</year><volume>10</volume><fpage>48</fpage><pub-id pub-id-type="pmcid">PMC2644678</pub-id><pub-id pub-id-type="pmid">19192299</pub-id><pub-id pub-id-type="doi">10.1186/1471-2105-10-48</pub-id></element-citation></ref><ref id="R21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Embree-Ku</surname><given-names>M</given-names></name><name><surname>Boekelheide</surname><given-names>K</given-names></name></person-group><article-title>Absence of p53 and FasL has sexually dimorphic effects on both development and reproduction</article-title><source>Exp Biol Med (Maywood)</source><year>2002</year><volume>227</volume><fpage>545</fpage><lpage>553</lpage><pub-id pub-id-type="pmid">12094020</pub-id></element-citation></ref><ref id="R22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Feinberg</surname><given-names>AP</given-names></name><name><surname>Ohlsson</surname><given-names>R</given-names></name><name><surname>Henikoff</surname><given-names>S</given-names></name></person-group><article-title>The epigenetic progenitor origin of human cancer</article-title><source>Nat Rev Genet</source><year>2006</year><volume>7</volume><fpage>21</fpage><lpage>33</lpage><pub-id pub-id-type="pmid">16369569</pub-id></element-citation></ref><ref id="R23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fimia</surname><given-names>GM</given-names></name><name><surname>Stoykova</surname><given-names>A</given-names></name><name><surname>Romagnoli</surname><given-names>A</given-names></name><name><surname>Giunta</surname><given-names>L</given-names></name><name><surname>Di Bartolomeo</surname><given-names>S</given-names></name><name><surname>Nardacci</surname><given-names>R</given-names></name><name><surname>Corazzari</surname><given-names>M</given-names></name><name><surname>Fuoco</surname><given-names>C</given-names></name><name><surname>Ucar</surname><given-names>A</given-names></name><name><surname>Schwartz</surname><given-names>P</given-names></name><name><surname>Gruss</surname><given-names>P</given-names></name><etal/></person-group><article-title>Ambra1 regulates autophagy and development of the nervous system</article-title><source>Nature</source><year>2007</year><volume>447</volume><fpage>1121</fpage><lpage>1125</lpage><pub-id pub-id-type="pmid">17589504</pub-id></element-citation></ref><ref id="R24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Finch</surname><given-names>RA</given-names></name><name><surname>Donoviel</surname><given-names>DB</given-names></name><name><surname>Potter</surname><given-names>D</given-names></name><name><surname>Shi</surname><given-names>M</given-names></name><name><surname>Fan</surname><given-names>A</given-names></name><name><surname>Freed</surname><given-names>DD</given-names></name><name><surname>Wang</surname><given-names>C-Y</given-names></name><name><surname>Zambrowicz</surname><given-names>BP</given-names></name><name><surname>Ramirez-Solis</surname><given-names>R</given-names></name><name><surname>Sands</surname><given-names>AT</given-names></name><name><surname>Zhang</surname><given-names>N</given-names></name></person-group><article-title>mdmx is a negative regulator of p53 activity in vivo</article-title><source>Cancer Res</source><year>2002</year><volume>62</volume><fpage>3221</fpage><lpage>3225</lpage><pub-id pub-id-type="pmid">12036937</pub-id></element-citation></ref><ref id="R25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Funk</surname><given-names>JS</given-names></name><name><surname>Klimovich</surname><given-names>M</given-names></name><name><surname>Drangenstein</surname><given-names>D</given-names></name><name><surname>Pielhoop</surname><given-names>O</given-names></name><name><surname>Hunold</surname><given-names>P</given-names></name><name><surname>Borowek</surname><given-names>A</given-names></name><name><surname>Noeparast</surname><given-names>M</given-names></name><name><surname>Pavlakis</surname><given-names>E</given-names></name><name><surname>Neumann</surname><given-names>M</given-names></name><name><surname>Balourdas</surname><given-names>D-I</given-names></name><name><surname>Kochhan</surname><given-names>K</given-names></name><etal/></person-group><article-title>Deep CRISPR mutagenesis characterizes the functional diversity of TP53 mutations</article-title><source>Nat Genet</source><year>2025</year><volume>57</volume><fpage>140</fpage><lpage>153</lpage><pub-id pub-id-type="pmcid">PMC11735402</pub-id><pub-id pub-id-type="pmid">39774325</pub-id><pub-id pub-id-type="doi">10.1038/s41588-024-02039-4</pub-id></element-citation></ref><ref id="R26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gencel-Augusto</surname><given-names>J</given-names></name><name><surname>Lozano</surname><given-names>G</given-names></name></person-group><article-title>p53 tetramerization: at the center of the dominant-negative effect of mutant p53</article-title><source>Genes Dev</source><year>2020</year><volume>34</volume><fpage>1128</fpage><lpage>1146</lpage><pub-id pub-id-type="pmcid">PMC7462067</pub-id><pub-id pub-id-type="pmid">32873579</pub-id><pub-id pub-id-type="doi">10.1101/gad.340976.120</pub-id></element-citation></ref><ref id="R27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gener-Ricos</surname><given-names>G</given-names></name><name><surname>Bewersdorf</surname><given-names>JP</given-names></name><name><surname>Loghavi</surname><given-names>S</given-names></name><name><surname>Bataller</surname><given-names>A</given-names></name><name><surname>Goldberg</surname><given-names>AD</given-names></name><name><surname>Sasaki</surname><given-names>K</given-names></name><name><surname>Famulare</surname><given-names>C</given-names></name><name><surname>Takahashi</surname><given-names>K</given-names></name><name><surname>Issa</surname><given-names>GC</given-names></name><name><surname>Borthakur</surname><given-names>G</given-names></name><name><surname>Kadia</surname><given-names>TM</given-names></name><etal/></person-group><article-title><italic>TP53</italic> Y220C mutations in patients with myeloid malignancies</article-title><source>Leukemia &amp; Lymphoma</source><year>2024</year><volume>65</volume><fpage>1511</fpage><lpage>1515</lpage><pub-id pub-id-type="pmid">38856690</pub-id></element-citation></ref><ref id="R28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Greten</surname><given-names>FR</given-names></name><name><surname>Grivennikov</surname><given-names>SI</given-names></name></person-group><article-title>Inflammation and Cancer: Triggers, Mechanisms, and Consequences</article-title><source>Immunity</source><year>2019</year><volume>51</volume><fpage>27</fpage><lpage>41</lpage><pub-id pub-id-type="pmcid">PMC6831096</pub-id><pub-id pub-id-type="pmid">31315034</pub-id><pub-id pub-id-type="doi">10.1016/j.immuni.2019.06.025</pub-id></element-citation></ref><ref id="R29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guimond</surname><given-names>MJ</given-names></name><name><surname>Wang</surname><given-names>B</given-names></name><name><surname>Fujita</surname><given-names>J</given-names></name><name><surname>Terhorst</surname><given-names>C</given-names></name><name><surname>Croy</surname><given-names>BA</given-names></name></person-group><article-title>Pregnancy-associated uterine granulated metrial gland cells in mutant and transgenic mice</article-title><source>Am J Reprod Immunol</source><year>1996</year><volume>35</volume><fpage>501</fpage><lpage>509</lpage><pub-id pub-id-type="pmid">8792932</pub-id></element-citation></ref><ref id="R30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hainaut</surname><given-names>P</given-names></name><name><surname>Pfeifer</surname><given-names>GP</given-names></name></person-group><article-title>Somatic TP53 Mutations in the Era of Genome Sequencing</article-title><source>Cold Spring Harb Perspect Med</source><year>2016</year><volume>6</volume><elocation-id>a026179</elocation-id><pub-id pub-id-type="pmcid">PMC5088513</pub-id><pub-id pub-id-type="pmid">27503997</pub-id><pub-id pub-id-type="doi">10.1101/cshperspect.a026179</pub-id></element-citation></ref><ref id="R31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ham</surname><given-names>SW</given-names></name><name><surname>Jeon</surname><given-names>H-Y</given-names></name><name><surname>Jin</surname><given-names>X</given-names></name><name><surname>Kim</surname><given-names>E-J</given-names></name><name><surname>Kim</surname><given-names>J-K</given-names></name><name><surname>Shin</surname><given-names>YJ</given-names></name><name><surname>Lee</surname><given-names>Y</given-names></name><name><surname>Kim</surname><given-names>SH</given-names></name><name><surname>Lee</surname><given-names>SY</given-names></name><name><surname>Seo</surname><given-names>S</given-names></name><name><surname>Park</surname><given-names>MG</given-names></name><etal/></person-group><article-title>TP53 gain-of-function mutation promotes inflammation in glioblastoma</article-title><source>Cell Death Differ</source><year>2019</year><volume>26</volume><fpage>409</fpage><lpage>425</lpage><pub-id pub-id-type="pmcid">PMC6370770</pub-id><pub-id pub-id-type="pmid">29786075</pub-id><pub-id pub-id-type="doi">10.1038/s41418-018-0126-3</pub-id></element-citation></ref><ref id="R32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hanahan</surname><given-names>D</given-names></name></person-group><article-title>Hallmarks of Cancer: New Dimensions</article-title><source>Cancer Discovery</source><year>2022</year><volume>12</volume><fpage>31</fpage><lpage>46</lpage><pub-id pub-id-type="pmid">35022204</pub-id></element-citation></ref><ref id="R33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hanel</surname><given-names>W</given-names></name><name><surname>Marchenko</surname><given-names>N</given-names></name><name><surname>Xu</surname><given-names>S</given-names></name><name><surname>Yu</surname><given-names>SX</given-names></name><name><surname>Weng</surname><given-names>W</given-names></name><name><surname>Moll</surname><given-names>U</given-names></name></person-group><article-title>Two hot spot mutant p53 mouse models display differential gain of function in tumorigenesis</article-title><source>Cell Death Differ</source><year>2013</year><volume>20</volume><fpage>898</fpage><lpage>909</lpage><pub-id pub-id-type="pmcid">PMC3679454</pub-id><pub-id pub-id-type="pmid">23538418</pub-id><pub-id pub-id-type="doi">10.1038/cdd.2013.17</pub-id></element-citation></ref><ref id="R34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hollstein</surname><given-names>M</given-names></name><name><surname>Sidransky</surname><given-names>D</given-names></name><name><surname>Vogelstein</surname><given-names>B</given-names></name><name><surname>Harris</surname><given-names>CC</given-names></name></person-group><article-title>p53 mutations in human cancers</article-title><source>Science</source><year>1991</year><volume>253</volume><fpage>49</fpage><lpage>53</lpage><pub-id pub-id-type="pmid">1905840</pub-id></element-citation></ref><ref id="R35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>W</given-names></name></person-group><article-title>The role of p53 gene family in reproduction</article-title><source>Cold Spring Harb Perspect Biol</source><year>2009</year><volume>1</volume><elocation-id>a001073</elocation-id><pub-id pub-id-type="pmcid">PMC2882126</pub-id><pub-id pub-id-type="pmid">20457559</pub-id><pub-id pub-id-type="doi">10.1101/cshperspect.a001073</pub-id></element-citation></ref><ref id="R36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>W</given-names></name><name><surname>Feng</surname><given-names>Z</given-names></name><name><surname>Teresky</surname><given-names>AK</given-names></name><name><surname>Levine</surname><given-names>AJ</given-names></name></person-group><article-title>p53 regulates maternal reproduction through LIF</article-title><source>Nature</source><year>2007</year><volume>450</volume><fpage>721</fpage><lpage>724</lpage><pub-id pub-id-type="pmid">18046411</pub-id></element-citation></ref><ref id="R37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Humpton</surname><given-names>TJ</given-names></name><name><surname>Hock</surname><given-names>AK</given-names></name><name><surname>Maddocks</surname><given-names>ODK</given-names></name><name><surname>Vousden</surname><given-names>KH</given-names></name></person-group><article-title>p53-mediated adaptation to serine starvation is retained by a common tumour-derived mutant</article-title><source>Cancer Metab</source><year>2018</year><volume>6</volume><fpage>18</fpage><pub-id pub-id-type="pmcid">PMC6276204</pub-id><pub-id pub-id-type="pmid">30524726</pub-id><pub-id pub-id-type="doi">10.1186/s40170-018-0191-6</pub-id></element-citation></ref><ref id="R38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iwakuma</surname><given-names>T</given-names></name><name><surname>Parant</surname><given-names>JM</given-names></name><name><surname>Fasulo</surname><given-names>M</given-names></name><name><surname>Zwart</surname><given-names>E</given-names></name><name><surname>Jacks</surname><given-names>T</given-names></name><name><surname>de Vries</surname><given-names>A</given-names></name><name><surname>Lozano</surname><given-names>G</given-names></name></person-group><article-title>Mutation at p53 serine 389 does not rescue the embryonic lethality in mdm2 or mdm4 null mice</article-title><source>Oncogene</source><year>2004</year><volume>23</volume><fpage>7644</fpage><lpage>7650</lpage><pub-id pub-id-type="pmid">15361844</pub-id></element-citation></ref><ref id="R39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jacks</surname><given-names>T</given-names></name><name><surname>Remington</surname><given-names>L</given-names></name><name><surname>Williams</surname><given-names>BO</given-names></name><name><surname>Schmitt</surname><given-names>EM</given-names></name><name><surname>Halachmi</surname><given-names>S</given-names></name><name><surname>Bronson</surname><given-names>RT</given-names></name><name><surname>Weinberg</surname><given-names>RA</given-names></name></person-group><article-title>Tumor spectrum analysis in p53-mutant mice</article-title><source>Curr Biol</source><year>1994</year><volume>4</volume><fpage>1</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">7922305</pub-id></element-citation></ref><ref id="R40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Joerger</surname><given-names>AC</given-names></name><name><surname>Ang</surname><given-names>HC</given-names></name><name><surname>Fersht</surname><given-names>AR</given-names></name></person-group><article-title>Structural basis for understanding oncogenic p53 mutations and designing rescue drugs</article-title><source>Proc Natl Acad Sci U S A</source><year>2006</year><volume>103</volume><fpage>15056</fpage><lpage>15061</lpage><pub-id pub-id-type="pmcid">PMC1635156</pub-id><pub-id pub-id-type="pmid">17015838</pub-id><pub-id pub-id-type="doi">10.1073/pnas.0607286103</pub-id></element-citation></ref><ref id="R41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jones</surname><given-names>SN</given-names></name><name><surname>Roe</surname><given-names>AE</given-names></name><name><surname>Donehower</surname><given-names>LA</given-names></name><name><surname>Bradley</surname><given-names>A</given-names></name></person-group><article-title>Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53</article-title><source>Nature</source><year>1995</year><volume>378</volume><fpage>206</fpage><lpage>208</lpage><pub-id pub-id-type="pmid">7477327</pub-id></element-citation></ref><ref id="R42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kadosh</surname><given-names>E</given-names></name><name><surname>Snir-Alkalay</surname><given-names>I</given-names></name><name><surname>Venkatachalam</surname><given-names>A</given-names></name><name><surname>May</surname><given-names>S</given-names></name><name><surname>Lasry</surname><given-names>A</given-names></name><name><surname>Elyada</surname><given-names>E</given-names></name><name><surname>Zinger</surname><given-names>A</given-names></name><name><surname>Shaham</surname><given-names>M</given-names></name><name><surname>Vaalani</surname><given-names>G</given-names></name><name><surname>Mernberger</surname><given-names>M</given-names></name><name><surname>Stiewe</surname><given-names>T</given-names></name><etal/></person-group><article-title>The gut microbiome switches mutant p53 from tumour-suppressive to oncogenic</article-title><source>Nature</source><year>2020</year><volume>586</volume><fpage>133</fpage><lpage>138</lpage><pub-id pub-id-type="pmcid">PMC7116712</pub-id><pub-id pub-id-type="pmid">32728212</pub-id><pub-id pub-id-type="doi">10.1038/s41586-020-2541-0</pub-id></element-citation></ref><ref id="R43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karthik</surname><given-names>KV</given-names></name><name><surname>Rajalingam</surname><given-names>A</given-names></name><name><surname>Shivashankar</surname><given-names>M</given-names></name><name><surname>Ganjiwale</surname><given-names>A</given-names></name></person-group><article-title>Recursive Feature Elimination-based Biomarker Identification for Open Neural Tube Defects</article-title><source>Curr Genomics</source><year>2022</year><volume>23</volume><fpage>195</fpage><lpage>206</lpage><pub-id pub-id-type="pmcid">PMC9878829</pub-id><pub-id pub-id-type="pmid">36777008</pub-id><pub-id pub-id-type="doi">10.2174/1389202923666220511162038</pub-id></element-citation></ref><ref id="R44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kastan</surname><given-names>MB</given-names></name><name><surname>Zhan</surname><given-names>Q</given-names></name><name><surname>el-Deiry</surname><given-names>WS</given-names></name><name><surname>Carrier</surname><given-names>F</given-names></name><name><surname>Jacks</surname><given-names>T</given-names></name><name><surname>Walsh</surname><given-names>WV</given-names></name><name><surname>Plunkett</surname><given-names>BS</given-names></name><name><surname>Vogelstein</surname><given-names>B</given-names></name><name><surname>Fornace</surname><given-names>AJ</given-names></name></person-group><article-title>A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia</article-title><source>Cell</source><year>1992</year><volume>71</volume><fpage>587</fpage><lpage>597</lpage><pub-id pub-id-type="pmid">1423616</pub-id></element-citation></ref><ref id="R45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kennedy</surname><given-names>MC</given-names></name><name><surname>Lowe</surname><given-names>SW</given-names></name></person-group><article-title>Mutant p53: it’s not all one and the same</article-title><source>Cell Death Differ</source><year>2022</year><volume>29</volume><fpage>983</fpage><lpage>987</lpage><pub-id pub-id-type="pmcid">PMC9090915</pub-id><pub-id pub-id-type="pmid">35361963</pub-id><pub-id pub-id-type="doi">10.1038/s41418-022-00989-y</pub-id></element-citation></ref><ref id="R46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>E</given-names></name><name><surname>Deppert</surname><given-names>W</given-names></name></person-group><article-title>Interactions of mutant p53 with DNA: guilt by association</article-title><source>Oncogene</source><year>2007</year><volume>26</volume><fpage>2185</fpage><lpage>2190</lpage><pub-id pub-id-type="pmid">17401427</pub-id></element-citation></ref><ref id="R47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>MP</given-names></name><name><surname>Lozano</surname><given-names>G</given-names></name></person-group><article-title>Mutant p53 partners in crime</article-title><source>Cell Death Differ</source><year>2018</year><volume>25</volume><fpage>161</fpage><lpage>168</lpage><pub-id pub-id-type="pmcid">PMC5729539</pub-id><pub-id pub-id-type="pmid">29099488</pub-id><pub-id pub-id-type="doi">10.1038/cdd.2017.185</pub-id></element-citation></ref><ref id="R48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kotler</surname><given-names>E</given-names></name><name><surname>Shani</surname><given-names>O</given-names></name><name><surname>Goldfeld</surname><given-names>G</given-names></name><name><surname>Lotan-Pompan</surname><given-names>M</given-names></name><name><surname>Tarcic</surname><given-names>O</given-names></name><name><surname>Gershoni</surname><given-names>A</given-names></name><name><surname>Hopf</surname><given-names>TA</given-names></name><name><surname>Marks</surname><given-names>DS</given-names></name><name><surname>Oren</surname><given-names>M</given-names></name><name><surname>Segal</surname><given-names>E</given-names></name></person-group><article-title>A Systematic p53 Mutation Library Links Differential Functional Impact to Cancer Mutation Pattern and Evolutionary Conservation</article-title><source>Mol Cell</source><year>2018</year><volume>71</volume><fpage>178</fpage><lpage>190</lpage><elocation-id>e8</elocation-id><pub-id pub-id-type="pmcid">PMC6127029</pub-id><pub-id pub-id-type="pmid">30193102</pub-id><pub-id pub-id-type="doi">10.1016/j.molcel.2018.08.013</pub-id></element-citation></ref><ref id="R49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kroemer</surname><given-names>G</given-names></name><name><surname>Pouyssegur</surname><given-names>J</given-names></name></person-group><article-title>Tumor Cell Metabolism: Cancer’s Achilles’ Heel</article-title><source>Cancer Cell</source><year>2008</year><volume>13</volume><fpage>472</fpage><lpage>482</lpage><pub-id pub-id-type="pmid">18538731</pub-id></element-citation></ref><ref id="R50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lallemand</surname><given-names>Y</given-names></name><name><surname>Luria</surname><given-names>V</given-names></name><name><surname>Haffner-Krausz</surname><given-names>R</given-names></name><name><surname>Lonai</surname><given-names>P</given-names></name></person-group><article-title>Maternally expressed PGK-Cre transgene as a tool for early and uniform activation of the Cre site-specific recombinase</article-title><source>Transgenic Res</source><year>1998</year><volume>7</volume><fpage>105</fpage><lpage>112</lpage><pub-id pub-id-type="pmid">9608738</pub-id></element-citation></ref><ref id="R51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lian</surname><given-names>Q</given-names></name><name><surname>Dheen</surname><given-names>ST</given-names></name><name><surname>Liao</surname><given-names>D</given-names></name><name><surname>Tay</surname><given-names>SSW</given-names></name></person-group><article-title>Enhanced inflammatory response in neural tubes of embryos derived from diabetic mice exposed to a teratogen</article-title><source>J of Neuroscience Research</source><year>2004</year><volume>75</volume><fpage>554</fpage><lpage>564</lpage><pub-id pub-id-type="pmid">14743439</pub-id></element-citation></ref><ref id="R52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liao</surname><given-names>Y</given-names></name><name><surname>Smyth</surname><given-names>GK</given-names></name><name><surname>Shi</surname><given-names>W</given-names></name></person-group><article-title>featureCounts: an efficient general purpose program for assigning sequence reads to genomic features</article-title><source>Bioinformatics</source><year>2014</year><volume>30</volume><fpage>923</fpage><lpage>930</lpage><pub-id pub-id-type="pmid">24227677</pub-id></element-citation></ref><ref id="R53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Yang</surname><given-names>J</given-names></name><name><surname>Pan</surname><given-names>Q</given-names></name><name><surname>Wang</surname><given-names>Xiangyu</given-names></name><name><surname>Wang</surname><given-names>Xinyin</given-names></name><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>Zheng</surname><given-names>X</given-names></name><name><surname>Huang</surname><given-names>Q</given-names></name></person-group><article-title>MDM4 was associated with poor prognosis and tumor-immune infiltration of cancers</article-title><source>Eur J Med Res</source><year>2024</year><volume>29</volume><fpage>79</fpage><pub-id pub-id-type="pmcid">PMC10821240</pub-id><pub-id pub-id-type="pmid">38281029</pub-id><pub-id pub-id-type="doi">10.1186/s40001-024-01684-z</pub-id></element-citation></ref><ref id="R54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Love</surname><given-names>MI</given-names></name><name><surname>Huber</surname><given-names>W</given-names></name><name><surname>Anders</surname><given-names>S</given-names></name></person-group><article-title>Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2</article-title><source>Genome Biol</source><year>2014</year><volume>15</volume><fpage>550</fpage><pub-id pub-id-type="pmcid">PMC4302049</pub-id><pub-id pub-id-type="pmid">25516281</pub-id><pub-id pub-id-type="doi">10.1186/s13059-014-0550-8</pub-id></element-citation></ref><ref id="R55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lowe</surname><given-names>SW</given-names></name><name><surname>Schmitt</surname><given-names>EM</given-names></name><name><surname>Smith</surname><given-names>SW</given-names></name><name><surname>Osborne</surname><given-names>BA</given-names></name><name><surname>Jacks</surname><given-names>T</given-names></name></person-group><article-title>p53 is required for radiation-induced apoptosis in mouse thymocytes</article-title><source>Nature</source><year>1993</year><volume>362</volume><fpage>847</fpage><lpage>849</lpage><pub-id pub-id-type="pmid">8479522</pub-id></element-citation></ref><ref id="R56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marine</surname><given-names>J-C</given-names></name><name><surname>Francoz</surname><given-names>S</given-names></name><name><surname>Maetens</surname><given-names>M</given-names></name><name><surname>Wahl</surname><given-names>G</given-names></name><name><surname>Toledo</surname><given-names>F</given-names></name><name><surname>Lozano</surname><given-names>G</given-names></name></person-group><article-title>Keeping p53 in check: essential and synergistic functions of Mdm2 and Mdm4</article-title><source>Cell Death Differ</source><year>2006</year><volume>13</volume><fpage>927</fpage><lpage>934</lpage><pub-id pub-id-type="pmid">16543935</pub-id></element-citation></ref><ref id="R57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McCann</surname><given-names>JJ</given-names></name><name><surname>Vasilevskaya</surname><given-names>IA</given-names></name><name><surname>McNair</surname><given-names>C</given-names></name><name><surname>Gallagher</surname><given-names>P</given-names></name><name><surname>Neupane</surname><given-names>NP</given-names></name><name><surname>De Leeuw</surname><given-names>R</given-names></name><name><surname>Shafi</surname><given-names>AA</given-names></name><name><surname>Dylgjeri</surname><given-names>E</given-names></name><name><surname>Mandigo</surname><given-names>AC</given-names></name><name><surname>Schiewer</surname><given-names>MJ</given-names></name><name><surname>Knudsen</surname><given-names>KE</given-names></name></person-group><article-title>Mutant p53 elicits context-dependent pro-tumorigenic phenotypes</article-title><source>Oncogene</source><year>2022</year><volume>41</volume><fpage>444</fpage><lpage>458</lpage><pub-id pub-id-type="pmcid">PMC8755525</pub-id><pub-id pub-id-type="pmid">34773073</pub-id><pub-id pub-id-type="doi">10.1038/s41388-021-01903-5</pub-id></element-citation></ref><ref id="R58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McNairn</surname><given-names>AJ</given-names></name><name><surname>Chuang</surname><given-names>C-H</given-names></name><name><surname>Bloom</surname><given-names>JC</given-names></name><name><surname>Wallace</surname><given-names>MD</given-names></name><name><surname>Schimenti</surname><given-names>JC</given-names></name></person-group><article-title>Female-biased embryonic death from inflammation induced by genomic instability</article-title><source>Nature</source><year>2019</year><volume>567</volume><fpage>105</fpage><lpage>108</lpage><pub-id pub-id-type="pmcid">PMC6497049</pub-id><pub-id pub-id-type="pmid">30787433</pub-id><pub-id pub-id-type="doi">10.1038/s41586-019-0936-6</pub-id></element-citation></ref><ref id="R59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Migliorini</surname><given-names>D</given-names></name><name><surname>Lazzerini Denchi</surname><given-names>E</given-names></name><name><surname>Danovi</surname><given-names>D</given-names></name><name><surname>Jochemsen</surname><given-names>A</given-names></name><name><surname>Capillo</surname><given-names>M</given-names></name><name><surname>Gobbi</surname><given-names>A</given-names></name><name><surname>Helin</surname><given-names>K</given-names></name><name><surname>Pelicci</surname><given-names>PG</given-names></name><name><surname>Marine</surname><given-names>J-C</given-names></name></person-group><article-title>Mdm4 (Mdmx) regulates p53-induced growth arrest and neuronal cell death during early embryonic mouse development</article-title><source>Mol Cell Biol</source><year>2002</year><volume>22</volume><fpage>5527</fpage><lpage>5538</lpage><pub-id pub-id-type="pmcid">PMC133932</pub-id><pub-id pub-id-type="pmid">12101245</pub-id><pub-id pub-id-type="doi">10.1128/MCB.22.15.5527-5538.2002</pub-id></element-citation></ref><ref id="R60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Montes de Oca Luna</surname><given-names>R</given-names></name><name><surname>Wagner</surname><given-names>DS</given-names></name><name><surname>Lozano</surname><given-names>G</given-names></name></person-group><article-title>Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53</article-title><source>Nature</source><year>1995</year><volume>378</volume><fpage>203</fpage><lpage>206</lpage><pub-id pub-id-type="pmid">7477326</pub-id></element-citation></ref><ref id="R61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morselli</surname><given-names>E</given-names></name><name><surname>Tasdemir</surname><given-names>E</given-names></name><name><surname>Maiuri</surname><given-names>MC</given-names></name><name><surname>Galluzzi</surname><given-names>L</given-names></name><name><surname>Kepp</surname><given-names>O</given-names></name><name><surname>Criollo</surname><given-names>A</given-names></name><name><surname>Vicencio</surname><given-names>JM</given-names></name><name><surname>Soussi</surname><given-names>T</given-names></name><name><surname>Kroemer</surname><given-names>G</given-names></name></person-group><article-title>Mutant p53 protein localized in the cytoplasm inhibits autophagy</article-title><source>Cell Cycle</source><year>2008</year><volume>7</volume><fpage>3056</fpage><lpage>3061</lpage><pub-id pub-id-type="pmid">18818522</pub-id></element-citation></ref><ref id="R62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pal</surname><given-names>A</given-names></name><name><surname>Gonzalez-Malerva</surname><given-names>L</given-names></name><name><surname>Eaton</surname><given-names>S</given-names></name><name><surname>Xu</surname><given-names>C</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Grief</surname><given-names>D</given-names></name><name><surname>Sakala</surname><given-names>L</given-names></name><name><surname>Nwekwo</surname><given-names>L</given-names></name><name><surname>Zeng</surname><given-names>J</given-names></name><name><surname>Christensen</surname><given-names>G</given-names></name><name><surname>Gupta</surname><given-names>C</given-names></name><etal/></person-group><article-title>Multidimensional quantitative phenotypic and molecular analysis reveals neomorphic behaviors of p53 missense mutants</article-title><source>NPJ Breast Cancer</source><year>2023</year><volume>9</volume><fpage>78</fpage><pub-id pub-id-type="pmcid">PMC10541912</pub-id><pub-id pub-id-type="pmid">37773066</pub-id><pub-id pub-id-type="doi">10.1038/s41523-023-00582-7</pub-id></element-citation></ref><ref id="R63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parant</surname><given-names>J</given-names></name><name><surname>Chavez-Reyes</surname><given-names>A</given-names></name><name><surname>Little</surname><given-names>NA</given-names></name><name><surname>Yan</surname><given-names>W</given-names></name><name><surname>Reinke</surname><given-names>V</given-names></name><name><surname>Jochemsen</surname><given-names>AG</given-names></name><name><surname>Lozano</surname><given-names>G</given-names></name></person-group><article-title>Rescue of embryonic lethality in Mdm4-null mice by loss of Trp53 suggests a nonoverlapping pathway with MDM2 to regulate p53</article-title><source>Nat Genet</source><year>2001</year><volume>29</volume><fpage>92</fpage><lpage>95</lpage><pub-id pub-id-type="pmid">11528400</pub-id></element-citation></ref><ref id="R64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pfister</surname><given-names>NT</given-names></name><name><surname>Prives</surname><given-names>C</given-names></name></person-group><article-title>Transcriptional Regulation by Wild-Type and Cancer-Related Mutant Forms of p53</article-title><source>Cold Spring Harb Perspect Med</source><year>2017</year><volume>7</volume><elocation-id>a026054</elocation-id><pub-id pub-id-type="pmcid">PMC5287061</pub-id><pub-id pub-id-type="pmid">27836911</pub-id><pub-id pub-id-type="doi">10.1101/cshperspect.a026054</pub-id></element-citation></ref><ref id="R65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rakotopare</surname><given-names>J</given-names></name><name><surname>Lejour</surname><given-names>V</given-names></name><name><surname>Duval</surname><given-names>C</given-names></name><name><surname>Eldawra</surname><given-names>E</given-names></name><name><surname>Escoffier</surname><given-names>H</given-names></name><name><surname>Toledo</surname><given-names>F</given-names></name></person-group><article-title>A systematic approach identifies p53-DREAM pathway target genes associated with blood or brain abnormalities</article-title><source>Dis Model Mech</source><year>2023</year><volume>16</volume><elocation-id>dmm050376</elocation-id><pub-id pub-id-type="pmcid">PMC10581385</pub-id><pub-id pub-id-type="pmid">37661832</pub-id><pub-id pub-id-type="doi">10.1242/dmm.050376</pub-id></element-citation></ref><ref id="R66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rakotopare</surname><given-names>J</given-names></name><name><surname>Toledo</surname><given-names>F</given-names></name></person-group><article-title>p53 in the Molecular Circuitry of Bone Marrow Failure Syndromes</article-title><source>Int J Mol Sci</source><year>2023</year><volume>24</volume><elocation-id>14940</elocation-id><pub-id pub-id-type="pmcid">PMC10573108</pub-id><pub-id pub-id-type="pmid">37834388</pub-id><pub-id pub-id-type="doi">10.3390/ijms241914940</pub-id></element-citation></ref><ref id="R67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rambold</surname><given-names>AS</given-names></name><name><surname>Lippincott-Schwartz</surname><given-names>J</given-names></name></person-group><article-title>Mechanisms of mitochondria and autophagy crosstalk</article-title><source>Cell Cycle</source><year>2011</year><volume>10</volume><fpage>4032</fpage><lpage>4038</lpage><pub-id pub-id-type="pmcid">PMC3272286</pub-id><pub-id pub-id-type="pmid">22101267</pub-id><pub-id pub-id-type="doi">10.4161/cc.10.23.18384</pub-id></element-citation></ref><ref id="R68"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Regeling</surname><given-names>A</given-names></name><name><surname>Armata</surname><given-names>HL</given-names></name><name><surname>Gallant</surname><given-names>J</given-names></name><name><surname>Jones</surname><given-names>SN</given-names></name><name><surname>Sluss</surname><given-names>HK</given-names></name></person-group><article-title>Mice defective in p53 nuclear localization signal 1 exhibit exencephaly</article-title><source>Transgenic Res</source><year>2011</year><volume>20</volume><fpage>899</fpage><lpage>912</lpage><pub-id pub-id-type="pmcid">PMC4234151</pub-id><pub-id pub-id-type="pmid">21127973</pub-id><pub-id pub-id-type="doi">10.1007/s11248-010-9468-4</pub-id></element-citation></ref><ref id="R69"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rockwell</surname><given-names>NC</given-names></name><name><surname>Yang</surname><given-names>W</given-names></name><name><surname>Warrington</surname><given-names>NM</given-names></name><name><surname>Staller</surname><given-names>MV</given-names></name><name><surname>Griffith</surname><given-names>M</given-names></name><name><surname>Griffith</surname><given-names>OL</given-names></name><name><surname>Gurnett</surname><given-names>CA</given-names></name><name><surname>Cohen</surname><given-names>BA</given-names></name><name><surname>Baldridge</surname><given-names>D</given-names></name><name><surname>Rubin</surname><given-names>JB</given-names></name></person-group><article-title>Sex- and Mutation-Specific p53 Gain-of-Function Activity in Gliomagenesis</article-title><source>Cancer Research Communications</source><year>2021</year><volume>1</volume><fpage>148</fpage><lpage>163</lpage><pub-id pub-id-type="pmcid">PMC8694557</pub-id><pub-id pub-id-type="pmid">34957471</pub-id><pub-id pub-id-type="doi">10.1158/2767-9764.CRC-21-0026</pub-id></element-citation></ref><ref id="R70"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rodier</surname><given-names>F</given-names></name><name><surname>Coppé</surname><given-names>J-P</given-names></name><name><surname>Patil</surname><given-names>CK</given-names></name><name><surname>Hoeijmakers</surname><given-names>WAM</given-names></name><name><surname>Muñoz</surname><given-names>DP</given-names></name><name><surname>Raza</surname><given-names>SR</given-names></name><name><surname>Freund</surname><given-names>A</given-names></name><name><surname>Campeau</surname><given-names>E</given-names></name><name><surname>Davalos</surname><given-names>AR</given-names></name><name><surname>Campisi</surname><given-names>J</given-names></name></person-group><article-title>Persistent DNA damage signalling triggers senescence-associated inflammatory cytokine secretion</article-title><source>Nat Cell Biol</source><year>2009</year><volume>11</volume><fpage>973</fpage><lpage>979</lpage><pub-id pub-id-type="pmcid">PMC2743561</pub-id><pub-id pub-id-type="pmid">19597488</pub-id><pub-id pub-id-type="doi">10.1038/ncb1909</pub-id></element-citation></ref><ref id="R71"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sah</surname><given-names>VP</given-names></name><name><surname>Attardi</surname><given-names>LD</given-names></name><name><surname>Mulligan</surname><given-names>GJ</given-names></name><name><surname>Williams</surname><given-names>BO</given-names></name><name><surname>Bronson</surname><given-names>RT</given-names></name><name><surname>Jacks</surname><given-names>T</given-names></name></person-group><article-title>A subset of p53-deficient embryos exhibit exencephaly</article-title><source>Nat Genet</source><year>1995</year><volume>10</volume><fpage>175</fpage><lpage>180</lpage><pub-id pub-id-type="pmid">7663512</pub-id></element-citation></ref><ref id="R72"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shirole</surname><given-names>N</given-names></name><name><surname>Pal</surname><given-names>D</given-names></name><name><surname>Kastenhuber</surname><given-names>E</given-names></name><name><surname>Senturk</surname><given-names>S</given-names></name><name><surname>Boroda</surname><given-names>J</given-names></name><name><surname>Pisterzi</surname><given-names>P</given-names></name><name><surname>Miller</surname><given-names>M</given-names></name><name><surname>Munoz</surname><given-names>G</given-names></name><name><surname>Anderluh</surname><given-names>M</given-names></name><name><surname>Ladanyi</surname><given-names>M</given-names></name><name><surname>Lowe</surname><given-names>S</given-names></name><etal/></person-group><article-title>TP53 exon-6 truncating mutations produce separation of function isoforms with pro-tumorigenic functions</article-title><source>Elife</source><year>2016</year><elocation-id>e17929</elocation-id><pub-id pub-id-type="pmcid">PMC5092050</pub-id><pub-id pub-id-type="pmid">27759562</pub-id><pub-id pub-id-type="doi">10.7554/eLife.17929</pub-id></element-citation></ref><ref id="R73"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Simeonova</surname><given-names>I</given-names></name><name><surname>Jaber</surname><given-names>S</given-names></name><name><surname>Draskovic</surname><given-names>I</given-names></name><name><surname>Bardot</surname><given-names>B</given-names></name><name><surname>Fang</surname><given-names>M</given-names></name><name><surname>Bouarich-Bourimi</surname><given-names>R</given-names></name><name><surname>Lejour</surname><given-names>V</given-names></name><name><surname>Charbonnier</surname><given-names>L</given-names></name><name><surname>Soudais</surname><given-names>C</given-names></name><name><surname>Bourdon</surname><given-names>JC</given-names></name><name><surname>Huerre</surname><given-names>M</given-names></name><etal/></person-group><article-title>Mutant mice lacking the p53 C-terminal domain model telomere syndromes</article-title><source>Cell Rep</source><year>2013</year><volume>3</volume><fpage>2046</fpage><lpage>2058</lpage><pub-id pub-id-type="pmid">23770245</pub-id></element-citation></ref><ref id="R74"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Simeonova</surname><given-names>I</given-names></name><name><surname>Lejour</surname><given-names>V</given-names></name><name><surname>Bardot</surname><given-names>B</given-names></name><name><surname>Bouarich-Bourimi</surname><given-names>R</given-names></name><name><surname>Morin</surname><given-names>A</given-names></name><name><surname>Fang</surname><given-names>M</given-names></name><name><surname>Charbonnier</surname><given-names>L</given-names></name><name><surname>Toledo</surname><given-names>F</given-names></name></person-group><article-title>Fuzzy Tandem Repeats Containing p53 Response Elements May Define Species-Specific p53 Target Genes</article-title><source>PLoS Genet</source><year>2012</year><volume>8</volume><elocation-id>e1002731</elocation-id><pub-id pub-id-type="pmcid">PMC3386156</pub-id><pub-id pub-id-type="pmid">22761580</pub-id><pub-id pub-id-type="doi">10.1371/journal.pgen.1002731</pub-id></element-citation></ref><ref id="R75"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sionov</surname><given-names>RV</given-names></name><name><surname>Vlahopoulos</surname><given-names>SA</given-names></name><name><surname>Granot</surname><given-names>Z</given-names></name></person-group><article-title>Regulation of Bim in Health and Disease</article-title><source>Oncotarget</source><year>2015</year><volume>6</volume><fpage>23058</fpage><lpage>23134</lpage><pub-id pub-id-type="pmcid">PMC4695108</pub-id><pub-id pub-id-type="pmid">26405162</pub-id><pub-id pub-id-type="doi">10.18632/oncotarget.5492</pub-id></element-citation></ref><ref id="R76"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Solier</surname><given-names>S</given-names></name><name><surname>Müller</surname><given-names>S</given-names></name><name><surname>Cañeque</surname><given-names>T</given-names></name><name><surname>Versini</surname><given-names>A</given-names></name><name><surname>Mansart</surname><given-names>A</given-names></name><name><surname>Sindikubwabo</surname><given-names>F</given-names></name><name><surname>Baron</surname><given-names>L</given-names></name><name><surname>Emam</surname><given-names>L</given-names></name><name><surname>Gestraud</surname><given-names>P</given-names></name><name><surname>Pantoș</surname><given-names>GD</given-names></name><name><surname>Gandon</surname><given-names>V</given-names></name><etal/></person-group><article-title>A druggable copper-signalling pathway that drives inflammation</article-title><source>Nature</source><year>2023</year><volume>617</volume><fpage>386</fpage><lpage>394</lpage><pub-id pub-id-type="pmcid">PMC10131557</pub-id><pub-id pub-id-type="pmid">37100912</pub-id><pub-id pub-id-type="doi">10.1038/s41586-023-06017-4</pub-id></element-citation></ref><ref id="R77"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stein</surname><given-names>Y</given-names></name><name><surname>Aloni-Grinstein</surname><given-names>R</given-names></name><name><surname>Rotter</surname><given-names>V</given-names></name></person-group><article-title>Mutant p53 oncogenicity: dominant-negative or gain-of-function?</article-title><source>Carcinogenesis</source><year>2020</year><volume>41</volume><fpage>1635</fpage><lpage>1647</lpage><pub-id pub-id-type="pmid">33159515</pub-id></element-citation></ref><ref id="R78"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Subramanian</surname><given-names>A</given-names></name><name><surname>Tamayo</surname><given-names>P</given-names></name><name><surname>Mootha</surname><given-names>VK</given-names></name><name><surname>Mukherjee</surname><given-names>S</given-names></name><name><surname>Ebert</surname><given-names>BL</given-names></name><name><surname>Gillette</surname><given-names>MA</given-names></name><name><surname>Paulovich</surname><given-names>A</given-names></name><name><surname>Pomeroy</surname><given-names>SL</given-names></name><name><surname>Golub</surname><given-names>TR</given-names></name><name><surname>Lander</surname><given-names>ES</given-names></name><name><surname>Mesirov</surname><given-names>JP</given-names></name></person-group><article-title>Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles</article-title><source>Proc Natl Acad Sci USA</source><year>2005</year><volume>102</volume><fpage>15545</fpage><lpage>15550</lpage><pub-id pub-id-type="pmcid">PMC1239896</pub-id><pub-id pub-id-type="pmid">16199517</pub-id><pub-id pub-id-type="doi">10.1073/pnas.0506580102</pub-id></element-citation></ref><ref id="R79"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tateossian</surname><given-names>H</given-names></name><name><surname>Morse</surname><given-names>S</given-names></name><name><surname>Simon</surname><given-names>MM</given-names></name><name><surname>Dean</surname><given-names>CH</given-names></name><name><surname>Brown</surname><given-names>SDM</given-names></name></person-group><article-title>Interactions between the otitis media gene, <italic>Fbxo11</italic>, and <italic>p53</italic> in the mouse embryonic lung</article-title><source>Disease Models &amp; Mechanisms</source><year>2015</year><elocation-id>dmm.022426</elocation-id><pub-id pub-id-type="pmcid">PMC4728322</pub-id><pub-id pub-id-type="pmid">26471094</pub-id><pub-id pub-id-type="doi">10.1242/dmm.022426</pub-id></element-citation></ref><ref id="R80"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Taylor</surname><given-names>AW</given-names></name><name><surname>Ng</surname><given-names>TF</given-names></name></person-group><article-title>Negative regulators that mediate ocular immune privilege</article-title><source>J Leukoc Biol</source><year>2018</year><pub-id pub-id-type="pmcid">PMC6240388</pub-id><pub-id pub-id-type="pmid">29431864</pub-id><pub-id pub-id-type="doi">10.1002/JLB.3MIR0817-337R</pub-id></element-citation></ref><ref id="R81"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Toledo</surname><given-names>F</given-names></name><name><surname>Krummel</surname><given-names>KA</given-names></name><name><surname>Lee</surname><given-names>CJ</given-names></name><name><surname>Liu</surname><given-names>C-W</given-names></name><name><surname>Rodewald</surname><given-names>L-W</given-names></name><name><surname>Tang</surname><given-names>M</given-names></name><name><surname>Wahl</surname><given-names>GM</given-names></name></person-group><article-title>A mouse p53 mutant lacking the proline-rich domain rescues Mdm4 deficiency and provides insight into the Mdm2-Mdm4-p53 regulatory network</article-title><source>Cancer Cell</source><year>2006</year><volume>9</volume><fpage>273</fpage><lpage>285</lpage><pub-id pub-id-type="pmid">16616333</pub-id></element-citation></ref><ref id="R82"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tseng</surname><given-names>T-H</given-names></name><name><surname>Wang</surname><given-names>C-J</given-names></name><name><surname>Lee</surname><given-names>Y-J</given-names></name><name><surname>Shao</surname><given-names>Y-C</given-names></name><name><surname>Shen</surname><given-names>C-H</given-names></name><name><surname>Lee</surname><given-names>K-C</given-names></name><name><surname>Tung</surname><given-names>S-Y</given-names></name><name><surname>Kuo</surname><given-names>H-C</given-names></name></person-group><article-title>Suppression of the Proliferation of Huh7 Hepatoma Cells Involving the Downregulation of Mutant p53 Protein and Inactivation of the STAT 3 Pathway with Ailanthoidol</article-title><source>Int J Mol Sci</source><year>2022</year><volume>23</volume><fpage>5102</fpage><pub-id pub-id-type="pmcid">PMC9099615</pub-id><pub-id pub-id-type="pmid">35563493</pub-id><pub-id pub-id-type="doi">10.3390/ijms23095102</pub-id></element-citation></ref><ref id="R83"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Varner</surname><given-names>MW</given-names></name><name><surname>Costantine</surname><given-names>MM</given-names></name><name><surname>Jablonski</surname><given-names>KA</given-names></name><name><surname>Rouse</surname><given-names>DJ</given-names></name><name><surname>Mercer</surname><given-names>BM</given-names></name><name><surname>Leveno</surname><given-names>KJ</given-names></name><name><surname>Reddy</surname><given-names>UM</given-names></name><name><surname>Buhimschi</surname><given-names>C</given-names></name><name><surname>Wapner</surname><given-names>RJ</given-names></name><name><surname>Sorokin</surname><given-names>Y</given-names></name><name><surname>Thorp</surname><given-names>JM</given-names></name><etal/></person-group><article-title>Sex-Specific Genetic Susceptibility to Adverse Neurodevelopmental Outcome in Offspring of Pregnancies at Risk of Early Preterm Delivery</article-title><source>Am J Perinatol</source><year>2020</year><volume>37</volume><fpage>281</fpage><lpage>290</lpage><pub-id pub-id-type="pmcid">PMC6685763</pub-id><pub-id pub-id-type="pmid">30731481</pub-id><pub-id pub-id-type="doi">10.1055/s-0039-1678535</pub-id></element-citation></ref><ref id="R84"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vassilev</surname><given-names>LT</given-names></name><name><surname>Vu</surname><given-names>BT</given-names></name><name><surname>Graves</surname><given-names>B</given-names></name><name><surname>Carvajal</surname><given-names>D</given-names></name><name><surname>Podlaski</surname><given-names>F</given-names></name><name><surname>Filipovic</surname><given-names>Z</given-names></name><name><surname>Kong</surname><given-names>N</given-names></name><name><surname>Kammlott</surname><given-names>U</given-names></name><name><surname>Lukacs</surname><given-names>C</given-names></name><name><surname>Klein</surname><given-names>C</given-names></name><name><surname>Fotouhi</surname><given-names>N</given-names></name><etal/></person-group><article-title>In vivo activation of the p53 pathway by small-molecule antagonists of MDM2</article-title><source>Science</source><year>2004</year><volume>303</volume><fpage>844</fpage><lpage>848</lpage><pub-id pub-id-type="pmid">14704432</pub-id></element-citation></ref><ref id="R85"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ventura</surname><given-names>A</given-names></name><name><surname>Kirsch</surname><given-names>DG</given-names></name><name><surname>McLaughlin</surname><given-names>ME</given-names></name><name><surname>Tuveson</surname><given-names>DA</given-names></name><name><surname>Grimm</surname><given-names>J</given-names></name><name><surname>Lintault</surname><given-names>L</given-names></name><name><surname>Newman</surname><given-names>J</given-names></name><name><surname>Reczek</surname><given-names>EE</given-names></name><name><surname>Weissleder</surname><given-names>R</given-names></name><name><surname>Jacks</surname><given-names>T</given-names></name></person-group><article-title>Restoration of p53 function leads to tumour regression in vivo</article-title><source>Nature</source><year>2007</year><volume>445</volume><fpage>661</fpage><lpage>665</lpage><pub-id pub-id-type="pmid">17251932</pub-id></element-citation></ref><ref id="R86"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vikhanskaya</surname><given-names>F</given-names></name><name><surname>Lee</surname><given-names>MK</given-names></name><name><surname>Mazzoletti</surname><given-names>M</given-names></name><name><surname>Broggini</surname><given-names>M</given-names></name><name><surname>Sabapathy</surname><given-names>K</given-names></name></person-group><article-title>Cancer-derived p53 mutants suppress p53-target gene expression--potential mechanism for gain of function of mutant p53</article-title><source>Nucleic Acids Res</source><year>2007</year><volume>35</volume><fpage>2093</fpage><lpage>2104</lpage><pub-id pub-id-type="pmcid">PMC1874625</pub-id><pub-id pub-id-type="pmid">17344317</pub-id><pub-id pub-id-type="doi">10.1093/nar/gkm099</pub-id></element-citation></ref><ref id="R87"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Voskarides</surname><given-names>K</given-names></name><name><surname>Giannopoulou</surname><given-names>N</given-names></name></person-group><article-title>The Role of TP53 in Adaptation and Evolution</article-title><source>Cells</source><year>2023</year><volume>12</volume><fpage>512</fpage><pub-id pub-id-type="pmcid">PMC9914165</pub-id><pub-id pub-id-type="pmid">36766853</pub-id><pub-id pub-id-type="doi">10.3390/cells12030512</pub-id></element-citation></ref><ref id="R88"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vousden</surname><given-names>KH</given-names></name><name><surname>Lane</surname><given-names>DP</given-names></name></person-group><article-title>p53 in health and disease</article-title><source>Nat Rev Mol Cell Biol</source><year>2007</year><volume>8</volume><fpage>275</fpage><lpage>283</lpage><pub-id pub-id-type="pmid">17380161</pub-id></element-citation></ref><ref id="R89"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Burigotto</surname><given-names>M</given-names></name><name><surname>Ghetti</surname><given-names>S</given-names></name><name><surname>Vaillant</surname><given-names>F</given-names></name><name><surname>Tan</surname><given-names>T</given-names></name><name><surname>Capaldo</surname><given-names>B</given-names></name><name><surname>Palmieri</surname><given-names>M</given-names></name><name><surname>Hirokawa</surname><given-names>Y</given-names></name><name><surname>Tai</surname><given-names>L</given-names></name><name><surname>Simpson</surname><given-names>D</given-names></name><name><surname>Chang</surname><given-names>C</given-names></name><etal/></person-group><article-title>Loss-of-function but not gain-of-function properties of mutant TP53 are critical for the proliferation, survival and metastasis of a broad range of cancer cells</article-title><source>Cancer Discov</source><year>2023</year><pub-id pub-id-type="pmcid">PMC10850947</pub-id><pub-id pub-id-type="pmid">37877779</pub-id><pub-id pub-id-type="doi">10.1158/2159-8290.CD-23-0402</pub-id></element-citation></ref><ref id="R90"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xiong</surname><given-names>S</given-names></name><name><surname>Chachad</surname><given-names>D</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Gencel-Augusto</surname><given-names>J</given-names></name><name><surname>Sirito</surname><given-names>M</given-names></name><name><surname>Pant</surname><given-names>V</given-names></name><name><surname>Yang</surname><given-names>P</given-names></name><name><surname>Sun</surname><given-names>C</given-names></name><name><surname>Chau</surname><given-names>G</given-names></name><name><surname>Qi</surname><given-names>Y</given-names></name><name><surname>Su</surname><given-names>X</given-names></name><etal/></person-group><article-title>Differential Gain-of-Function Activity of Three p53 Hotspot Mutants In Vivo</article-title><source>Cancer Research</source><year>2022</year><volume>82</volume><fpage>1926</fpage><lpage>1936</lpage><pub-id pub-id-type="pmcid">PMC9117479</pub-id><pub-id pub-id-type="pmid">35320355</pub-id><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-21-3376</pub-id></element-citation></ref><ref id="R91"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>J</given-names></name><name><surname>Qian</surname><given-names>J</given-names></name><name><surname>Hu</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Zhou</surname><given-names>X</given-names></name><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>Fang</surname><given-names>J-Y</given-names></name></person-group><article-title>Heterogeneity of Li-Fraumeni Syndrome links to unequal gain-of-function effects of p53 mutations</article-title><source>Sci Rep</source><year>2014</year><volume>4</volume><elocation-id>4223</elocation-id><pub-id pub-id-type="pmcid">PMC3936234</pub-id><pub-id pub-id-type="pmid">24573247</pub-id><pub-id pub-id-type="doi">10.1038/srep04223</pub-id></element-citation></ref><ref id="R92"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ye</surname><given-names>J</given-names></name><name><surname>Tong</surname><given-names>Y</given-names></name><name><surname>Lv</surname><given-names>J</given-names></name><name><surname>Peng</surname><given-names>R</given-names></name><name><surname>Chen</surname><given-names>S</given-names></name><name><surname>Kuang</surname><given-names>L</given-names></name><name><surname>Su</surname><given-names>K</given-names></name><name><surname>Zheng</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>T</given-names></name><name><surname>Zhang</surname><given-names>F</given-names></name><name><surname>Jin</surname><given-names>L</given-names></name><etal/></person-group><article-title>Rare mutations in the autophagy-regulating gene AMBRA1 contribute to human neural tube defects</article-title><source>Hum Mutat</source><year>2020</year><volume>41</volume><fpage>1383</fpage><lpage>1393</lpage><pub-id pub-id-type="pmid">32333458</pub-id></element-citation></ref><ref id="R93"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Wei</surname><given-names>H</given-names></name></person-group><article-title>Role of Decidual Natural Killer Cells in Human Pregnancy and Related Pregnancy Complications</article-title><source>Front Immunol</source><year>2021</year><volume>12</volume><elocation-id>728291</elocation-id><pub-id pub-id-type="pmcid">PMC8426434</pub-id><pub-id pub-id-type="pmid">34512661</pub-id><pub-id pub-id-type="doi">10.3389/fimmu.2021.728291</pub-id></element-citation></ref><ref id="R94"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>J</given-names></name><name><surname>Tian</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Qu</surname><given-names>L</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>Q</given-names></name><name><surname>Luo</surname><given-names>Y</given-names></name><name><surname>Wu</surname><given-names>X</given-names></name></person-group><article-title>p53 Mutant p53 <sup>N236S</sup> Induces Neural Tube Defects in Female Embryos</article-title><source>Int J Biol Sci</source><year>2019</year><volume>15</volume><fpage>2006</fpage><lpage>2015</lpage><pub-id pub-id-type="pmcid">PMC6743294</pub-id><pub-id pub-id-type="pmid">31523200</pub-id><pub-id pub-id-type="doi">10.7150/ijbs.31451</pub-id></element-citation></ref><ref id="R95"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>M</given-names></name><name><surname>Chen</surname><given-names>Y-H</given-names></name><name><surname>Dong</surname><given-names>X-T</given-names></name><name><surname>Zhou</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Wu</surname><given-names>S-X</given-names></name><name><surname>Xia</surname><given-names>M-Z</given-names></name><name><surname>Zhang</surname><given-names>C</given-names></name><name><surname>Xu</surname><given-names>D-X</given-names></name></person-group><article-title>Folic Acid Protects against Lipopolysaccharide-Induced Preterm Delivery and Intrauterine Growth Restriction through Its Anti-Inflammatory Effect in Mice</article-title><source>PLoS ONE</source><year>2013</year><volume>8</volume><elocation-id>e82713</elocation-id><pub-id pub-id-type="pmcid">PMC3855776</pub-id><pub-id pub-id-type="pmid">24324824</pub-id><pub-id pub-id-type="doi">10.1371/journal.pone.0082713</pub-id></element-citation></ref><ref id="R96"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>M</given-names></name><name><surname>Wang</surname><given-names>T</given-names></name><name><surname>Gleber-Netto</surname><given-names>FO</given-names></name><name><surname>Chen</surname><given-names>Z</given-names></name><name><surname>McGrail</surname><given-names>DJ</given-names></name><name><surname>Gomez</surname><given-names>JA</given-names></name><name><surname>Ju</surname><given-names>W</given-names></name><name><surname>Gadhikar</surname><given-names>MA</given-names></name><name><surname>Ma</surname><given-names>W</given-names></name><name><surname>Shen</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>Q</given-names></name><etal/></person-group><article-title>Mutant p53 gains oncogenic functions through a chromosomal instability-induced cytosolic DNA response</article-title><source>Nat Commun</source><year>2024</year><volume>15</volume><fpage>180</fpage><pub-id pub-id-type="pmcid">PMC10761733</pub-id><pub-id pub-id-type="pmid">38167338</pub-id><pub-id pub-id-type="doi">10.1038/s41467-023-44239-2</pub-id></element-citation></ref><ref id="R97"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>J</given-names></name><name><surname>Luo</surname><given-names>J</given-names></name><name><surname>Peiwei</surname><given-names>Li</given-names></name><name><surname>Zhou</surname><given-names>Y</given-names></name><name><surname>Peichao</surname><given-names>Li</given-names></name><name><surname>Wang</surname><given-names>F</given-names></name><name><surname>Mallio</surname><given-names>CA</given-names></name><name><surname>Rossi</surname><given-names>G</given-names></name><name><surname>Jalal</surname><given-names>AH</given-names></name><name><surname>Filipovic</surname><given-names>N</given-names></name><name><surname>Tian</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Triptolide promotes degradation of the unfolded gain-of-function Tp53R175H/Y220C mutant protein by initiating heat shock protein 70 transcription in non-small cell lung cancer</article-title><source>Transl Lung Cancer Res</source><year>2022</year><volume>11</volume><fpage>802</fpage><lpage>816</lpage><pub-id pub-id-type="pmcid">PMC9186163</pub-id><pub-id pub-id-type="pmid">35693277</pub-id><pub-id pub-id-type="doi">10.21037/tlcr-22-312</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="F1" position="float"><label>Figure 1</label><caption><title>Targeting the Y217C missense mutation at the mouse <italic>Trp53</italic> locus.</title><p><bold>(A)</bold> Targeting strategy. The wildtype (WT) <italic>Trp53</italic> gene is within a 17 kb-long EcoRI (RI) fragment (black boxes are for coding sequences and white boxes for UTRs). The targeting construct contains: (1) a 1.5 kb-long 5’ homology region; (2) a Lox-Stop-Lox (LSL) cassette with a <italic>neomycin</italic> selection gene (Neo), four transcriptional stops (STOP) and an EcoRI site, flanked by LoxP sites (arrowheads); (3) p53 coding exons, including the Y217C (YC) missense mutation in exon 6 (asterisk) and an additional BanII site; (4) a 2.8 kb-long 3’ homology region; and (5) the diphteria α-toxin (DTA) gene for targeting enrichment. Proper recombinants with a <italic>Trp53</italic><sup>LSL-Y217C</sup> allele, resulting from the described crossing-overs, were G418 resistant. They were identified by a 2.4 kb-long band after PCR with primers a and b, and confirmed by bands of 635 and 224 bp after PCR with primers c and d and BanII digestion. They were also verified by Southern blot with the indicated probe as containing a 10.5 kb EcoRI band. Two recombinant ES clones were injected into blastocysts to generate chimeras, and germline transmission was verified by genotyping with primers c and d and BanII digestion. Excision of the LSL cassette was performed <italic>in vivo</italic>, by breeding <italic>Trp53</italic><sup>+/LSL-Y217C</sup> male mice with females carrying the PGK-<italic>Cre</italic> transgene, to obtain mice with a <italic>Trp53</italic><sup>Y217C</sup> allele. <bold>(B-D)</bold> Screening of recombinant ES clones (+) by PCR with primers a and b (B); PCR with primers c and d then BanII digestion (C); Southern blot (D). <bold>(E)</bold> Genotyping of mouse embryonic fibroblasts (MEFs) from an intercross of <italic>Trp53</italic><sup>+/Y217C</sup> mice, by PCR with primers c and d and BanII digestion. <bold>(F)</bold> <italic>Trp53</italic><sup>Y217C</sup> sequence around codon 217. The introduced Y217C missense mutation and the silent mutation creating an additional BanII restriction site are highlighted (asterisks). <bold>(G)</bold> WT and <italic>Trp53</italic><sup>Y217C/Y217C</sup> (YC/YC) MEFs express similar p53 mRNA levels. Total RNA was extracted, then p53 mRNAs were quantified by real-time qPCR, normalized to control mRNAs and the amount in WT cells was assigned the value of 1. Primer sequences are listed in <xref ref-type="supplementary-material" rid="SD1">Table S8</xref>.</p></caption><graphic xlink:href="EMS199093-f001"/></fig><fig id="F2" position="float"><label>Figure 2</label><caption><title><italic>Trp53</italic><sup>Y217C/Y217C</sup> cells exhibit alterations in p53 abundance and subcellular localization, defective responses to DNA damage, and increased chromosomal instability.</title><p><bold>(A)</bold> Increased p53 protein levels in <italic>Trp53</italic><sup>Y217C/Y217C</sup> and <italic>Trp53</italic><sup>+/Y217C</sup> MEFs. MEFs of the indicated genotypes were treated or not with 10 μM Nutlin 3a for 24 h, then protein extracts were immunoblotted with antibodies against Mdm2, p53, p21 and actin. <bold>(B)</bold> The transactivation of classical p53 target genes <italic>Cdkn1a/p21</italic> and <italic>Mdm2</italic> is impaired in <italic>Trp53</italic><sup>Y217C/Y217C</sup> cells. WT, <italic>Trp53</italic><sup>Y217C/Y217C</sup> and <italic>Trp53</italic><sup>-/-</sup> MEFs were treated as in (A), then (top) mRNAs were quantified in 5-6 independent experiments using real-time PCR, with results normalized to control mRNAs and mean RNA amounts in unstressed WT cells assigned a value of 1; or (bottom) ChIP assays were performed at the <italic>Cdkn1a</italic> and <italic>Mdm2</italic> promoters in 2-3 independent experiments with an antibody against p53 or rabbit IgG as a negative control. Immunoprecipitates were quantified using real-time PCR, normalized to data over an irrelevant region, and the amount in unstressed WT cells was assigned a value of 1. <bold>(C)</bold> Assessment of p53<sup>WT</sup> and p53<sup>Y217C</sup> subcellular localization by cellular fractionation. WT and <italic>Trp53</italic><sup>Y217C/Y217C</sup> MEFs were treated or not with 1 μM doxorubicin (Doxo) for 24 hr, submitted to cellular fractionation, then protein extracts were immunoblotted with antibodies against p53 or the fraction controls Tubulin for cytoplasm (Cp.), Nup98 for nucleoplasm (Np.) and histone H3 for chromatin (χin). <bold>(D)</bold> Assessment of p53<sup>WT</sup> and p53<sup>Y217C</sup> subcellular localization by immunofluorescence. WT, <italic>Trp53</italic><sup>Y217C/Y217C</sup> and <italic>Trp53</italic><sup>-/-</sup> MEFs were treated with 10 μM Nutlin 3a for 24 h, then stained with antibodies against p53 (red) or actin (green) and DNA was counterstained with DAPI (blue). <bold>(E)</bold> Absence of a cell cycle arrest response in <italic>Trp53</italic><sup>Y217C/Y217C</sup> MEFs. Asynchronous cell populations of <italic>Trp53</italic><sup>+/+</sup>, <italic>Trp53</italic><sup>Y217C/Y217C</sup> and <italic>Trp53</italic><sup>-/-</sup> MEFs were analyzed 24 hr after 0, 3 or 12 Gy ɣ-irradiation. Results from 3 independent experiments. <bold>(F)</bold> Absence of a p53-dependent apoptotic response in <italic>Trp53</italic><sup>Y217C/Y217C</sup> thymocytes. Age-matched mice of the indicated genotypes were left untreated or submitted to 10 Gy whole-body ɣ-irradiation then sacrificed after 4 hr and their thymocytes were stained with Annexin V-FITC and analyzed by FACS, in 2 independent experiments. <bold>(G)</bold> Increased chromosomal instability in <italic>Trp53</italic><sup>Y217C/Y217C</sup> fibroblasts. Metaphase spreads were prepared from WT, <italic>Trp53</italic><sup>Y217C/Y217C</sup> and <italic>Trp53</italic><sup>-/-</sup> MEFs at passage 4, then aberrant metaphases (with chromosome breaks, radial chromosomes or DMs) were scored. Left: distribution of aberrant metaphases. Data from 110 WT, 97 <italic>Trp53</italic><sup>Y217C/Y217C</sup> or 119 <italic>Trp53</italic><sup>-/-</sup> complete diploid metaphases, independently observed by two experimenters. Right: examples of two aberrant <italic>Trp53</italic><sup>Y217C/Y217C</sup> metaphases: one with a double minute chromosome (DM), a chromosome break (Br) and a radial chromosome (R), the other with multiple DMs. Enlargements of regions of interest are presented between the two metaphases. Scale bars (D, G): 5 μm. ***P&lt;0.001, **P&lt;0.01, *P&lt;0.05, °P=0.09, ns: non-significant by Student’s t (B, E, F) or Fischer’s (G) tests.</p></caption><graphic xlink:href="EMS199093-f002"/></fig><fig id="F3" position="float"><label>Figure 3</label><caption><title><italic>Trp53</italic><sup>Y217C/Y217C</sup> mice exhibit female-specific perinatal lethality.</title><p><bold>(A)</bold> Distribution of weaned mice obtained from <italic>Trp53</italic><sup>+/-</sup> or <italic>Trp53</italic><sup>+/Y217C</sup> intercrosses. Obs: observed numbers of mice at weaning (P21); exp: expected numbers assuming a Mendelian distribution without sex distortion; f/m: observed female/male ratios. Consistent with previous reports, the observed distribution of weaned mice from <italic>Trp53</italic><sup>+/-</sup> intercrosses did not conform to values expected for a Mendelian distribution without sex distortion (υ=5; χ<sup>2</sup>=16.31&gt;15.09), indicating a significant deficit in female <italic>Trp53</italic><sup>-/-</sup> mice (top). The distribution of weaned mice from <italic>Trp53</italic><sup>+/Y217C</sup> intercrosses diverged even more from values for a Mendelian distribution without sex distortion (υ =5; χ<sup>2</sup>=104.23&gt;15.09), due to a striking deficit in female <italic>Trp53</italic><sup>Y217C/Y217C</sup> mice (bottom). Differences between the frequencies of <italic>Trp53</italic><sup>Y217C/Y217C</sup> (4/677) and <italic>Trp53</italic><sup>-/-</sup> (8/196) females in the progeny, or between the female to male ratios for <italic>Trp53</italic><sup>Y217C/Y217C</sup> (4/75) and <italic>Trp53</italic><sup>-/-</sup> (8/28) animals, are statistically significant (P=0.0012 and P=0.0087 in Fischer’s tests, respectively). <bold>(B)</bold> Exencephaly is frequently observed in p53<sup>Y217C/Y217C</sup> female embryos. Top: the distribution of E12.5-16.5 embryos from heterozygous (<italic>Trp53</italic><sup>+/Y217C</sup>) intercrosses or heterozygous-homozygous (<italic>Trp53</italic><sup>+/Y217C</sup> x <italic>Trp53</italic><sup>Y217C/Y217C</sup>) crosses is shown. f or m exenc.: number of female or male embryos with exencephaly; o.a.: embryos with other abnormalities. Below, examples of female <italic>Trp53</italic><sup>Y217C/Y217C</sup> embryos at E12.5, 13.5 and 16.5 exhibiting exencephaly (arrows) are each shown (center) together with a normal embryo from the same litter (bottom). <bold>(C)</bold> Distribution of mice at birth from the indicated crosses. Of note, out of five <italic>Trp53</italic><sup>Y217C/Y217C</sup> females observed at birth, only one remained alive at weaning age. Thus, the female/male ratio for weaned <italic>Trp53</italic><sup>Y217C/Y217C</sup> animals from these crosses was 1/22, a ratio similar to the one observed in A (4/75).</p></caption><graphic xlink:href="EMS199093-f003"/></fig><fig id="F4" position="float"><label>Figure 4</label><caption><title>Oncogenic effects of the mutant protein in <italic>Trp53</italic><sup>Y217C/Y217C</sup> male mice.</title><p><bold>(A-B)</bold> In homozygous males, p53<sup>Y217C</sup> leads to accelerated tumor-induced death (A), and aggressive metastatic tumors (B); n=cohort size. <bold>(C)</bold> Hematoxylin and eosin (H&amp;E) staining of sections from the lung (top) and spleen (bottom) of <italic>Trp53</italic><sup>-/-</sup> and <italic>Trp53</italic><sup>Y217C/Y217C</sup> male mice, showing metastases in <italic>Trp53</italic><sup>Y217C/Y217C</sup> animals. Normal organ structures are shown, with “A” indicating pulmonary alveoli, and “WP” and “RP” standing for splenic white and red pulp, respectively. In the lung section of the <italic>Trp53</italic><sup>Y217C/Y217C</sup> mouse, the rectangle indicates a lymphoma area. In the spleen section of the <italic>Trp53</italic><sup>Y217C/Y217C</sup> mouse, the typical splenic structures are absent due to massive tissue homogenization of the spleen by lymphoma cells.</p></caption><graphic xlink:href="EMS199093-f004"/></fig><fig id="F5" position="float"><label>Figure 5</label><caption><title>Evidence of inflammation in <italic>Trp53</italic><sup>Y217C/Y217C</sup> mice.</title><p><bold>(A-B)</bold> RNAseq analysis of thymi from <italic>Trp53</italic><sup>Y217C/Y217C</sup> (n=3) and <italic>Trp53</italic><sup>-/-</sup> (n=3) 8 weeks-old male mice. Volcano plot (A), with differentially expressed genes (DEGs), downregulated (blue) or upregulated (red) in <italic>Trp53</italic><sup>Y217C/Y217C</sup> cells. Unsupervised clustering heat-map plot (B), with 192 DEGs ranked according to log<sub>2</sub> fold changes. <bold>(C)</bold> Gene Ontology (GO) analysis of DEGs. Out of 192 DEGs, 141 are associated with at least one GO term, according to the Gene Ontology enRIchment anaLysis and visuaLizAtion tool (GOrilla). For each GO term, enrichment was calculated by comparing with the full list of 19759 genes associated with a GO term, and results are presented here with a color scale according to P-value of enrichment. This analysis mainly revealed an enrichment for genes associated with white blood cell chemotaxis/migration and inflammation, as shown here. Complete results of the analysis are presented in <xref ref-type="supplementary-material" rid="SD1">Figure S11</xref>. <bold>(D)</bold> RT-qPCR analysis of the indicated genes in thymi from 8 weeks-old <italic>Trp53</italic><sup>+/+</sup>, <italic>Trp53</italic><sup>Y217C/Y217C</sup> and <italic>Trp53</italic><sup>-/-</sup> male mice. Means + s.e.m. (n=3 per genotype). ***P&lt;0.001, **P&lt;0.01, *P&lt;0.05, °P&lt;0.075 by Student’s t test. <bold>(E)</bold> Gene set enrichment analysis (GSEA) of transcriptomes from <italic>Trp53</italic><sup>Y217C/Y217C</sup> and <italic>Trp53</italic><sup>-/-</sup> thymic cells. GSEA identified 13 gene sets enriched in <italic>Trp53</italic><sup>Y217C/Y217C</sup> cells with normalized enrichment scores (NES) &gt; 2. Nominal p-values (NOM p-val) and false discovery rate q-values (FDR q-val) are indicated. <bold>(F)</bold> GSEA provides evidence of increased NC-NF-kB signaling in <italic>Trp53</italic><sup>Y217C/Y217C</sup> male thymocytes. Results are presented as in E. <bold>(G)</bold> Supformin (LCC-12), an anti-inflammatory molecule, increases the female to male ratio in <italic>Trp53</italic><sup>Y217C/Y217C</sup> weaned pups. <italic>Trp53</italic><sup>+/Y217C</sup> females were mated with <italic>Trp53</italic><sup>Y217C/Y217C</sup> males, then oral gavage of pregnant females with 5 mg/kg supformin was performed on the 10<sup>th</sup> and 11<sup>th</sup> days post-coitum, and their progeny was genotyped at weaning. The female to male (f/m) ratio for <italic>Trp53</italic><sup>Y217C/Y217C</sup> weaned pups that were exposed to supformin <italic>in utero</italic> (+) was compared to the f/m ratios for <italic>Trp53</italic><sup>-/-</sup> or <italic>Trp53</italic><sup>Y217C/Y217C</sup> weaned pups never exposed to supformin (-). Exposure to supformin led to a five-fold increase in the proportion of <italic>Trp53</italic><sup>Y217C/Y217C</sup> weaned females. **P&lt;0.01, °P=0.056, ns: non-significant by Fischer’s test.</p></caption><graphic xlink:href="EMS199093-f005"/></fig></floats-group></article>